cell_id,prompt,answer,output
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is JW-7-24-1. The drug SMILES structure is COC1=CC(=CC(=C1)C2=CC3=C4C(=CN=C3C=C2)C=CC(=O)N4C5=CC(=C(C=C5)N6CCNCC6)C(F)(F)F)OC. Drug target is LCK. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.JW-7-24-1 is a MAP3K1 activator. However, the cell line already has a MAP3K1 mutation, making it less likely for the drug to have a significant effect. Additionally, the cell line has other mutations that could contribute to drug resistance, such as U2AF1. However, there is no clear evidence that JW-7-24-1 is specifically resisted by cells with these mutations, and other factors, such as epigenetic modifications, could play a role in drug sensitivity. Therefore, the drug may still be effective against the cell line, but further research is needed to confirm this."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KIN001-260. The drug SMILES structure is C1CC1COC2=CC=CC(=O)C2=C3C=C(C(=C(N3)N)C#N)C4CCNCC4. Drug target is CDC7. Drug target pathway is DNA replication.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. KIN001-260 is a CDK1 inhibitor. CDK1 is not a target for FLT3, MAP3K1, NOTCH1, TP53, U2AF1 mutations. Therefore, the drug is expected to be resistant to the cell line with given mutations."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NSC-87877. The drug SMILES structure is C1=CC2=C(C(=O)C(=NNC3=CC4=C(C=C3)C=C(C=C4)S(=O)(=O)O)C=C2S(=O)(=O)O)N=C1. Drug target is SHP-1 (PTPN6), SHP-2 (PTPN11). Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
The cell line has mutations in MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, the drug target SHP-1 (PTPN6), SHP-2 (PTPN11) is other, which may make it less predictable in terms of drug sensitivity."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GNE-317. The drug SMILES structure is CC1=C(SC2=C1N=C(N=C2N3CCOCC3)C4=CN=C(N=C4)N)C5(COC5)OC. Drug target is PI3Kalpha. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
The cell line has mutations in MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, the drug GNE-317 is an inhibitor of PI3Kalpha, and the cell line has a mutation in the PIK3C2G gene, which encodes for PI3Kgamma, making it less sensitive to PI3K inhibitors."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NAVITOCLAX. The drug SMILES structure is CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C. Drug target is BCL2, BCL-XL, BCL-W. Drug target pathway is Apoptosis regulation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Drug NAVITOCLAX is an BCL-2 selective inhibitor. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which can make the cell line resistant to the drug."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PLX-4720. The drug SMILES structure is CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=NC=C(C=C23)Cl)F. Drug target is BRAF. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning: The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, making it resistant to PLX-4720. PLX-4720 is a BRAF inhibitor, but the cell line's resistance is not solely due to BRAF mutations. Instead, it has mutations in multiple signaling pathways, making it resistant to BRAF inhibitors."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ERK5-IN-1. The drug SMILES structure is CCOC1=C(C=CC(=C1)C(=O)N2CCC(CC2)N3CCN(CC3)C)NC4=NC=C5C(=N4)N(C6=CC=CC=C6C(=O)N5C)C7CCCC7. Drug target is ERK5, BET. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.ERK5-IN-1 is a selective ERK5 BET inhibitor. BET inhibitors have been shown to have antileukemia properties. The cell line in question has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which may contribute to its response to ERK5-IN-1. However, given the sensitivity of the cell line to ERK5-IN-1, it is likely that the drug is targeting the ERK5 pathway effectively in this case."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TGX-221. The drug SMILES structure is CC1=CN2C(=O)C=C(N=C2C(=C1)C(C)NC3=CC=CC=C3)N4CCOCC4. Drug target is PI3Kbeta. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning: TGX-221 is a PI3Kbeta inhibitor. PI3Kbeta signaling plays a role in the survival of FLT3-ITD and MAP3K1-mutated cells. The cell line in question has mutations in FLT3, MAP3K1, and TP53, but it does not have any PIK3C2G/PIK3R1 or PTEN mutations, which are commonly associated with PI3K/MTOR pathway dysregulation. Therefore, the drug SCC12 is expected to be effective against this cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is DASATINIB. The drug SMILES structure is CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=NC(=NC(=C3)N4CCN(CC4)CCO)C. Drug target is ABL, SRC, Ephrins, PDGFR, KIT. Drug target pathway is RTK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Dasatinib is a multikinase inhibitor that has been shown to be effective in CML and AML. It inhibits the ABL, SRC, Ephrins, PDGFR, KIT, and JAK3 kinases. In the case of the cell line with mutations in FLT3, MAP3K1, NOTCH1, P53, ASXL1, and U2AF1, dasatinib is expected to be effective due to its ability to inhibit FLT3 and other kinases that are relevant to the cell line. Additionally, ASXL1 mutations can lead to epigenetic changes that affect the expression of multiple genes, and dasatinib has been shown to have epigenetic effects that may contribute to its therapeutic effect."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ZM-447439. The drug SMILES structure is COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)NC(=O)C4=CC=CC=C4)OCCCN5CCOCC5. Drug target is AURKA, AURKB. Drug target pathway is Mitosis.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line is resistant to ZM-447439 due to mutations in MAP3K1 and NOTCH1. MAP3K1 mutations can lead to resistance to AURKA inhibitors. NOTCH1 mutations can contribute to resistance to various drugs, including AURKA inhibitors."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CGP-082996. The drug SMILES structure is CCNC1=CC(=NC(=N1)NC2=CC3=C(C=C2)N(C=C3)CC4=CC=CC=C4)NC5CCC(CC5)O. Drug target is CDK4. Drug target pathway is Cell cycle.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. CGP-082996 is a CDK4/6 inhibitor. The cell line has mutations in TP53 and U2AF1, which are associated with resistance to CDK4/6 inhibitors."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is UPROSERTIB. The drug SMILES structure is CN1C(=C(C=N1)Cl)C2=C(OC(=C2)C(=O)N[C@@H](CC3=CC(=C(C=C3)F)F)CN)Cl. Drug target is AKT1, AKT2, AKT3. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with resistance to UPROSERTIB."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is DORAMAPIMOD. The drug SMILES structure is CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCCN5CCOCC5. Drug target is p38, JNK2. Drug target pathway is JNK and p38 signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, the drug DORAMAPIMOD is an inhibitor of JNK and p38 signaling, and the cell line has mutations in these pathways (MAP3K1, TP53)."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AST-1306. The drug SMILES structure is C=CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=C(C=C3)OCC4=CC(=CC=C4)F)Cl. Drug target is EGFR, ERBB4. Drug target pathway is RTK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with resistance to AST-1306."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is WIKI4. The drug SMILES structure is COC1=CC=C(C=C1)N2C(=NN=C2SCCCN3C(=O)C4=CC=CC5=C4C(=CC=C5)C3=O)C6=CC=NC=C6. Drug target is TNKS1, TNKS2. Drug target pathway is WNT signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning: The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. WIKI4 is an ATR inhibitor. ATR is a key regulator of the S-phase checkpoint. Mutations in FLT3, NOTCH1, TP53, U2AF1 can confer resistance to ATR inhibitors. Additionally, MAP3K1 mutations can lead to resistance to various drugs, including those targeting the mitotic checkpoint."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is OLAPARIB. The drug SMILES structure is C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F. Drug target is PARP1, PARP2. Drug target pathway is Genome integrity.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in MAP3K1, NOTCH1, and TP53, which are associated with resistance to PARP inhibitors like olaparib."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AGI-6780. The drug SMILES structure is C1CC1NS(=O)(=O)C2=CC(=C(C=C2)C3=CSC=C3)NC(=O)NC4=CC=CC(=C4)C(F)(F)F. Drug target is IDH2(R140Q). Drug target pathway is Metabolism.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
AGI-6780 is an IDH2 inhibitor. IDH2 mutations are linked to a poor prognosis in multiple cancer types. In vitro studies have shown that AGI-6780 has antiproliferative effects on IDH2-mutant cells. The cell line in question has a NOTCH1 mutation, but NOTCH1 mutations are not necessarily associated with AGI-6780 resistance. In fact, NOTCH1 mutations have been linked to increased sensitivity to IDH2 inhibitors. Therefore, the cell line's mutation profile does not indicate resistance to AGI-6780."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CUDC-101. The drug SMILES structure is COC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCCCCCC(=O)NO. Drug target is HDAC1-10, EGFR, ERBB2. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning: The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, CUDC-101 is known to be resistant in FLT3-ITD positive acute myeloid leukemia."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SB-505124. The drug SMILES structure is CC1=NC(=CC=C1)C2=C(N=C(N2)C(C)(C)C)C3=CC4=C(C=C3)OCO4. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Sensitive.
Reasoning:
SB-505124 is a MAP3K1 inhibitor. MAP3K1 is upstream of ERK1 and ERK2. Mutations in FLT3, MAP3K1, NOTCH1, and TP53 are present in the cell line. However, these mutations do not confer resistance to SB-505124. In fact, MAP3K1 mutations have been shown to sensitize cells to SB-505124. Therefore, the drug is expected to be sensitive to the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZD8931. The drug SMILES structure is CNC(=O)CN1CCC(CC1)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC. Drug target is EGFR, ERBB2, ERBB3. Drug target pathway is RTK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
AZD8931 is a MEK1/2, AKT1, EGFR, ERBB2, EGFR TKI, EGFR mutation inhibitor. The mutations in the cell line include MAP3K1, NOTCH1, TP53. MAP3K1 is a positive regulator of the MAPK signaling pathway. NOTCH1 is a receptor that regulates gene expression. TP53 is the primary gene associated with the development of most human tumors. U2AF1 is a RNA-binding protein that plays a role in splicing. None of these mutations are directly related to the drug target pathway. Therefore, the drug Sensitivity is Sensitive."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is IMATINIB. The drug SMILES structure is CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5. Drug target is ABL, KIT, PDGFR. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
IMATINIB is a multikinase inhibitor that includes the ABL, KIT, and PDGFR kinases. IMATINIB is FDA-approved for the treatment of chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), gastrointestinal stromal tumors (GIST), and systemic mastocytosis. IMATINIB has been shown to have antiproliferative effects on various cancer cell lines, including CML, ALL, GIST, and other solid tumors.
The mutations in the cell line include ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1. ASXL1 mutations can contribute to the development of leukemia by impairing the epigenetic regulation of genes involved in cell proliferation and differentiation. FLT3 mutations can lead to FLT3 activation and uncontrolled cell growth. MAP3K1 mutations can contribute to the development of various types of cancer by activating the ERK signaling pathway"
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NVP-BHG712. The drug SMILES structure is CC1=C(C=C(C=C1)C(=O)NC2=CC=CC(=C2)C(F)(F)F)NC3=NC(=NC4=C3C=NN4C)C5=CN=CC=C5. Drug target is EPHB4, RAF, SRC, ABL. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, the drug NVP-BHG712 is an EPHB4, RAF, SRC, ABL inhibitor, and the cell line does not have a known mutation in EPHB4. Therefore, the drug is unlikely to be sensitive for this cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ZG-10. The drug SMILES structure is O=C(C1=CC=C(NC(C=CCN(C)C)=O)C=C1)NC2=CC(NC3=NC(C4=CC=CN=C4)=CC=N3)=CC=C2. Drug target is JNK1. Drug target pathway is JNK and p38 signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, ZG-10 is a JNK1 inhibitor, and the cell line does not have any reported JNK1 mutations. However, the cell line has mutations in MAP3K1, which is upstream of JNK1 in the signaling pathway, suggesting potential resistance to JNK1 inhibitors."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CX-5461. The drug SMILES structure is CC1=CN=C(C=N1)CNC(=O)C2=C3N(C4=CC=CC=C4S3)C5=C(C2=O)C=CC(=N5)N6CCCN(CC6)C. Drug target is RNA Polymerase 1. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in MAP3K1, NOTCH1, TP53, U2AF1, which are associated with resistance to CX-5461."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ERLOTINIB. The drug SMILES structure is COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC. Drug target is EGFR. Drug target pathway is EGFR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. ERLOTINIB is an EGFR inhibitor. The cell line has mutations in FLT3, MAP3K1, NOTCH1, and TP53, making it resistant to ERLOTINIB."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CMK. The drug SMILES structure is CC1=CC=C(C=C1)C2=C(N(C3=NC=NC(=C23)N)CCCO)C(=O)CCl. Drug target is RSK2. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Sensitive.
Reasoning:
The cell line has mutations in ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
The drug CMK is a kinase inhibitor. The cell line has a mutation in MAP3K1, which is the kinase AKT1, AKT2, and MAP3K1 are part of the PI3K/MTOR signaling pathway. The drug may inhibit the PI3K/MTOR signaling pathway in the cell line.
The cell line also has a mutation in FLT3, which is a receptor tyrosine kinase. The drug CMK may inhibit the FLT3 signaling pathway in the cell line.
The drug may also have off-target effects on other kinases, but the primary mechanism of action is likely to be the inhibition of the PI3K/MTOR signaling pathway and the FLT3 signaling pathway.
The cell line has mutations in TP53 and U2AF1, but these mutations are not directly related to the drug sensitivity of the drug CMK on the cell line.
Therefore, the drug Sensitivity is Sensitive."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LIMK1 INHIBITOR BMS4. The drug SMILES structure is CCNC(=O)NC1=NC=C(S1)C2=CC(=NC(=N2)C3=NC=CN=C3)C4=C(C=C(C=C4C)OC)C. Drug target is LIMK1. Drug target pathway is Cytoskeleton.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. The drug LIMK1 INHIBITOR BMS4 is an inhibitor of FLT3. However, the cell line's mutations are not primarily in FLT3, but rather in MAP3K1, NOTCH1, TP53, U2AF1. These mutations are more likely to contribute to the drug resistance or sensitivity of the cell line. Therefore, the drug sensitivity should be determined based on the mutational profile of the cell line and the drug-target interaction, rather than the drug structure alone. In this case, the drug LIMK1 INHIBITOR BMS4 is an inhibitor of FLT3, but the cell line has mutations in other genes that are more likely to contribute to the drug resistance or sensitivity. Therefore, the drug Sensitivity is Sensitive, but the reasoning is that the drug Sensitivity cannot be determined solely based on the drug structure and the drug target, but rather on the drug target pathway and the mutational profile of the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AT13148. The drug SMILES structure is C1=CC(=CC=C1C2=CNN=C2)[C@@](CN)(C3=CC=C(C=C3)Cl)O. Drug target is AKT1. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
AT13148 is a MAP3K1 inhibitor. The cell line has a mutation in MAP3K1. However, the cell line also has mutations in FLT3, NOTCH1, and TP53, which are known to be associated with resistance to MAP3K1 inhibitors. However, the cell line does not have any known resistance mutations in MAP3K1, such as BRAF or NF1. Additionally, the cell line does not have any known resistance mutations in other PI3K/MTOR signaling pathway genes, such as PTEN or PIK3C2g. Therefore, the drug is expected to be sensitive to the cell line based on the mutation profile."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FTI-277. The drug SMILES structure is COC(=O)[C@H](CCSC)NC(=O)C1=C(C=C(C=C1)NC[C@H](CS)N)C2=CC=CC=C2. Drug target is Farnesyl-transferase (FNTA). Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning: The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. FLT3 mutations can make cells resistant to FTI-277. MAP3K1 mutations can also contribute to resistance. Additionally, the presence of NOTCH1 and TP53 mutations can indicate resistance to various drugs. U2AF1 mutations can also contribute to drug resistance."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NVP-ADW742. The drug SMILES structure is C1CCN(C1)CC2CC(C2)N3C=C(C4=C3N=CN=C4N)C5=CC(=CC=C5)OCC6=CC=CC=C6. Drug target is IGF1R. Drug target pathway is IGF1R signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning:
The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. FLT3 mutations can make the cell line resistant to drugs such as NVP-ADW742. MAP3K1 mutations can also contribute to drug resistance. Additionally, the cell line has mutations in multiple genes that are commonly associated with resistance to various drugs. Therefore, the drug Sensitivity is Resistant."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ENZASTAURIN. The drug SMILES structure is CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7. Drug target is PKCB. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
ENZASTAURIN is a MAPK1, MAPK11, MAPK13 kinase inhibitor. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. FLT3 mutations can be resistant to FLT3 inhibitors, but ENZASTAURIN is a kinase inhibitor with multiple targets, and FLT3 is just one of them. MAP3K1 mutations can be resistant to MEK inhibitors, but ENZASTAURIN is a kinase inhibitor with multiple targets, and MAP3K1 is just one of them. NOTCH1 mutations can be resistant to NOTCH inhibitors, but ENZASTAURIN is a kinase inhibitor with multiple targets, and NOTCH1 is just one of them. TP53 mutations can be resistant to various drugs, but ENZASTAURIN is a kinase inhibitor with multiple targets, and TP53 mutations are not directly related to kinase inhibition. U2AF1 mutations can be resistant"
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NVP-TAE684. The drug SMILES structure is CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC. Drug target is ALK. Drug target pathway is RTK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, NVP-TAE684 is an ALK inhibitor, and the cell line does not have an ALK mutation. Therefore, the drug is unlikely to be sensitive for this cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FULVESTRANT. The drug SMILES structure is C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F. Drug target is ESR1. Drug target pathway is Hormone-related.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Fulvestrant is an estrogen receptor (ER) antagonist. However, the cell line has mutations in MAP3K1, NOTCH1, TP53, and U2AF1, which are associated with resistance to various drugs. In particular, mutations in MAP3K1 and NOTCH1 can contribute to resistance to ER antagonists like fulvestrant."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is WH-4-023. The drug SMILES structure is O=C(OC1=C(C)C=CC=C1C)N(C2=CC=C(OC)C=C2OC)C3=NC(NC4=CC=C(N5CCN(C)CC5)C=C4)=NC=C3. Drug target is SRC, LCK. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. WH-4-023 is a FLT3, IGF1R, and VEGFR kinase inhibitor. Resistance to FLT3 inhibitors can be caused by mutations in the FLT3 gene, such as FLT3 internal tandem duplication (ITD). In addition, epigenetic modifications, such as DNA methylation and histone acetylation, can contribute to FLT3 inhibitor resistance. The cell line in this case has mutations in ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which can contribute to drug resistance."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZD7762. The drug SMILES structure is C1C[C@H](CNC1)NC(=O)C2=C(C=C(S2)C3=CC(=CC=C3)F)NC(=O)N. Drug target is CHEK1, CHEK2. Drug target pathway is Cell cycle.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Sensitive.
Reasoning: AZD7762 is a CHEK1/2 inhibitor. The cell line has mutations in NOTCH1, MAP3K1, and TP53. NOTCH1 mutations can lead to resistance to various drugs, including those that inhibit the G2/M checkpoint. MAP3K1 mutations can also lead to resistance to various drugs, including those that inhibit the MEK1/2 pathway. TP53 mutations can lead to resistance to various drugs, including those that inhibit the G2/M checkpoint. However, AZD7762 is a CHEK1/2 inhibitor, and the cell line does not have a CHEK1/2 mutation. Therefore, the drug is expected to be effective against the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KIN001-244. The drug SMILES structure is C1=CC=C(C=C1)[C@H](COC2=CC3=C(C=C2)NC(=O)N3)NC(=O)C4=CC=CN(C4=O)CC5=CC(=C(C=C5)F)F. Drug target is PDK1. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with resistance to PDK1 inhibitors. PDK1 inhibitors, such as KIN001-244, are used to target the PI3K signaling pathway. However, these inhibitors may not be effective against cell lines with mutations in genes that regulate the PI3K pathway, such as FLT3, MAP3K1, and TP53. Additionally, the cell line has a mutation in U2AF1, which is a splicing factor and can lead to resistance to various drugs."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is QL-X-138. The drug SMILES structure is CC1=C(C=C(C=C1)N2C(=O)C=CC3=CN=C4C=CC(=CC4=C32)C5=CNN=C5)NC(=O)C=C. Drug target is BTK. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
The cell line has mutations in MAP3K1, NOTCH1, TP53, U2AF1, and FLT3 is amplified. These mutations are associated with resistance to QL-X-138."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AFATINIB. The drug SMILES structure is CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4. Drug target is EGFR, ERBB2. Drug target pathway is EGFR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. Afatinib is an ERBB2/ERBB1 receptor family blocker, but the cell line has mutations in MAP3K1, NOTCH1, and TP53, which can contribute to resistance to EGFR inhibitors."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BICALUTAMIDE. The drug SMILES structure is CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O. Drug target is AR. Drug target pathway is Hormone-related.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. Bicalutamide is an androgen receptor (AR) agonist. AR mutations and overexpression can contribute to resistance to AR-targeted therapies. The cell line in question has mutations in the AR gene, ASXL1, and TP53, which can contribute to resistance to AR-targeted therapies. Additionally, the cell line has mutations in MAP3K1, a gene that is often mutated in various cancers and can contribute to resistance to various treatments."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is METAP2 INHIBITOR, A832234. The drug SMILES structure is CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)NC(=O)CCl)OC)C. Drug target is MetAP2. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
Reasoning: The cell line has mutations in MAP3K1, NOTCH1, TP53. MAP3K1 mutations can lead to resistance to various drugs, including FLT3, NTRK, NUTM1, PARP1, PIK3CA, RAF, RAR, RB1, RET, ROS1, SLC34A2, TP53. NOTCH1 mutations can lead to resistance to BET inhibitors, CDK4/6 inhibitors, EGFR inhibitors, PI3K inhibitors, T-cell engagers, VEGF Trap. TP53 mutations can lead to resistance to ATR inhibitors, AXL, CDK12, EPH34, EPHB1, ERBB2, KLHL6, MLL, MLL2, MAP3K13, MDM4, MED12, MET, MKNK1, MSH2, MSH6, NBN, NF1, NF2, NKX2-1, PDGFRA, PIK3C2B,"
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LINSITINIB. The drug SMILES structure is CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O. Drug target is IGF1R. Drug target pathway is IGF1R signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
LINSITINIB is a reversible IGF1R inhibitor. IGF1R signaling plays a role in cell growth, metabolism, and survival. In a study, LINSITINIB in combination with CETUXIMAB showed synergistic effect in FLT3-ITD and KRAS mutant colorectal cancer cells. In the case of the cell line with mutations in FLT3, MAP3K1, NOTCH1, and TP53, the drug SENSITIVE is a suitable outcome as IGF1R signaling pathway is relevant to the cell line's mutations."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VISMODEGIB. The drug SMILES structure is CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl. Drug target is SMO. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
VISMODEGIB is a selective MEK1/2 inhibitor. The MAP3K1 gene mutation in the cell line is not listed, but it is a common mutation in AML. However, VISMODEGIB has been reported to have good activity in AML with MAP3K1 mutations. In vitro studies have shown that VISMODEGIB can induce apoptosis in AML cells with MAP3K1 mutations. Additionally, clinical trials have shown that VISMODEGIB can improve overall response rates and survival in AML patients, including those with MAP3K1 mutations. Therefore, VISMODEGIB is expected to be effective in the cell line with the given mutations."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FTY-720. The drug SMILES structure is CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N. Drug target is S1P. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
Reasoning: FTY-720 is an immunomodulator and S1P analog. In CLL, FTY-720 has been shown to have anti-proliferative effects. However, the mutations in the cell line, particularly MAP3K1, are associated with resistance to immunomodulators. Therefore, the drug is likely to be resistant in this case."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is 5-FLUOROURACIL. The drug SMILES structure is C1=C(C(=O)NC(=O)N1)F. Drug target is Antimetabolite (DNA & RNA). Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
5-Fluorouracil is an antimetabolite. It inhibits the synthesis of RNA and DNA. 5-Fluorouracil is commonly used in the treatment of colorectal cancer. The resistance of the cell line to 5-Fluorouracil can be due to various reasons such as mutations in the genes involved in the metabolism of 5-Fluorouracil, overexpression of certain genes, epigenetic modifications, etc. In this case, the cell line has mutations in ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1. ASXL1 mutations can lead to resistance to 5-Fluorouracil by impairing the DNA methylation process. MAP3K1 mutations can lead to resistance to 5-Fluorouracil by activating the MEK1 signaling pathway. FLT3 mutations can lead to resistance to 5-Fluorouracil by activating the FLT3 signaling pathway. Notch signaling pathway mutations can lead to resistance to 5-Fluorouracil by promoting cell survival and proliferation. TP53 mutations can lead to resistance to 5-Fluorour"
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BELINOSTAT. The drug SMILES structure is C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO. Drug target is HDAC1. Drug target pathway is Chromatin histone acetylation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, Belinostat is an HDAC1 inhibitor, and HDAC1 mutations can lead to drug resistance."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PEVONEDISTAT. The drug SMILES structure is C1CC2=CC=CC=C2[C@H]1NC3=NC=NC4=C3C=CN4[C@@H]5C[C@H]([C@H](C5)O)COS(=O)(=O)N. Drug target is NAE. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
Reasoning:
The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. Pevonedistat is an NAE drug. NAE drugs can affect various cellular processes, including protein folding, cell division, and apoptosis. Pevonedistat is a NAE drug that inhibits NEDD8-activating enzyme, which disrupts the NEDD8-activation pathway and leads to proteasome inhibition and apoptosis. However, the cell line has mutations in multiple genes that are involved in various cellular processes, including FLT3, MAP3K1, NOTCH1, TP53, U2AF1. These mutations can affect the drug sensitivity of the cell line to Pevonedistat. In particular, the cell line has mutations in TP53, which is a well-known tumor suppressor gene. TP53 mutations are often associated with resistance to various drugs, including Pevonedistat. Therefore, it is likely that the cell line is resistant to Pevonedistat due to its mutations."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is P22077. The drug SMILES structure is CC(=O)C1=CC(=C(S1)SC2=C(C=C(C=C2)F)F)[N+](=O)[O-]. Drug target is USP7, USP47. Drug target pathway is Protein stability and degradation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
The cell line has mutations in MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, the drug P22077 is a USP7, USP47 inhibitor, and the cell line does not have any known mutations in these targets. Therefore, the drug is likely to be resistant for this cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PAZOPANIB. The drug SMILES structure is CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N. Drug target is CSF1R, KIT,  PDGFRA, PDGFRB. Drug target pathway is RTK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive. PAZOPANIB is a multikinase inhibitor that has been shown to have activity against FLT3, KIT, PDGFRA, and VEGFRs. In the case of the given mutations, the cell line has mutations in ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1. ASXL1 and U2AF1 are epigenetic and splicing related genes, respectively. MAP3K1 is a kinase that is upstream of ERK. NOTCH1 is a receptor that plays a role in cellular differentiation and survival. TP53 is the tumor suppressor gene. The cell line has mutations in multiple genes that are involved in various signaling pathways, but it does not have any known mutations in KIT or PDGFRA, which are the targets of other multikinase inhibitors. Therefore, the mutation profile of the cell line does not suggest resistance to PAZOPANIB. Additionally, PAZOPANIB has been shown to have activity against FLT3, which is mutated in"
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BUPARLISIB. The drug SMILES structure is C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4. Drug target is PI3Kalpha, PI3Kdelta, PI3Kbeta, PI3Kgamma. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.BUPARLISIB is a PI3Kinase inhibitor. The cell line has mutations in NOTCH1, TP53, U2AF1, and the drug SMO16 is an inhibitor of FLT3. However, BUPARLISIB is a PI3Kinase inhibitor and the cell line has mutations in PI3K, PTEN, and TP53, making it resistant to BUPARLISIB."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SELUMETINIB. The drug SMILES structure is CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO. Drug target is MEK1, MEK2. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
SELUMETINIB is a MEK1, MEK2 inhibitor. The cell line has mutations in MAP3K1, which is the upstream kinase of ERK1 and ERK2. ERK1 and ERK2 are downstream of MEK1 and MAP3K1 mutations can lead to ERK signaling pathway dysregulation. However, the cell line does not have KRAS or BRAF mutations, which are common drivers of ERK signaling pathway dysregulation. In addition, the cell line does not have PIK3C2G or PTEN mutations, which are drivers of PI3K/MTOR pathway dysregulation, another common driver of ERK signaling pathway dysregulation. SELUMETINIB has been shown to be effective in MAP3K1 mutant cell lines. Therefore, SELUMETINIB is expected to be effective on this cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is OXALIPLATIN. The drug SMILES structure is C1CC[C@H]([C@@H](C1)N)N.C(=O)(C(=O)O)O.[Pt]. Drug target is DNA alkylating agent. Drug target pathway is DNA replication.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with resistance to oxaliplatin."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ALPELISIB. The drug SMILES structure is CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F. Drug target is PI3Kalpha. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning: The cell line has mutations in the MAP3K1 gene, which is the upstream kinase in the PI3K/MTOR signaling pathway. Mutations in MAP3K1 can lead to resistance to PI3K inhibitors like ALPELISIB. Additionally, the cell line has mutations in the TP53 gene, which can also contribute to resistance to various drugs."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TAMOXIFEN. The drug SMILES structure is CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3. Drug target is ESR1. Drug target pathway is Hormone-related.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. TAMOXIFEN is a selective estrogen receptor modulator. Resistance to TAMOXIFEN can be due to mutations in genes such as PIK3C2G, POLD1, TP53, U2AF1. In the case of the cell line with mutations ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1, resistance to TAMOXIFEN is expected due to the presence of multiple relevant mutations."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CAY10566. The drug SMILES structure is CC1=NN=C(O1)C2=NN=C(C=C2)N3CCC(CC3)OC4=C(C=CC(=C4)F)Cl. Drug target is Stearoyl-CoA desaturase. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning: The cell line does not have mutations in the MAP3K13 gene, which is the gene for AXL. AXL signaling can contribute to resistance to various drugs. The cell line also does not have mutations in the BRAF, EGFR, ERBB4, MLL2, MAP2K1, NOTCH3, PIK3CA, PTPN11, ROS1, and TMPRSS22 genes, which are commonly mutated in various cancers and can result in drug resistance. Additionally, the drug CAY10566 is a known inhibitor of FLT3, and the cell line does not have a FLT3 mutation. Therefore, the drug is expected to be sensitive to the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is WEE1 INHIBITOR. The drug SMILES structure is C1=CC=C(C(=C1)C2=CC3=C(C4=C(N3)C=CC(=C4)O)C5=C2C(=O)NC5=O)Cl. Drug target is WEE1, CHEK1. Drug target pathway is Cell cycle.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
The cell line has multiple mutations, including FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, the drug target WEE1, CHEK1 is not mutated in the cell line. Therefore, the drug is likely to be resistant for this cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZ-628. The drug SMILES structure is CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(C)(C)C#N)NC3=CC4=C(C=C3)N=CN(C4=O)C. Drug target is BRAF. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with resistance to AZ-628."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PIPERLONGUMINE. The drug SMILES structure is COC1=CC(=CC(=C1OC)OC)C=CC(=O)N2CCC=CC2=O. Drug target is Induces reactive oxygen species. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. Piperlongumine is a known sensitizer for FLT3-inhibitors. However, the cell line in question has a FLT3 mutation, but also has mutations in MAP3K1, NOTCH1, and TP53, which may contribute to its resistance to the drug."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LINIFANIB. The drug SMILES structure is CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N. Drug target is VEGFR1, VEGFR2, VEGFR3, CSF1R, FLT3, KIT. Drug target pathway is RTK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Sensitive.LINIFANIB is a multikinase inhibitor that has been shown to have antitumor effects in various hematological and solid tumors. The exact mechanism of action is not fully understood, but it is believed that LINIFANIB inhibits multiple RTKs, including VEGFR1, VEGFR2, VEGFR3, FLT3, KIT, and CSF1R, which may contribute to its antitumor activity. In the case of the cell line with mutations in FLT3, MAP3K1, NOTCH1, and TP53, the sensitivity to LINIFANIB may be enhanced due to the presence of these mutations. However, further research is needed to confirm this."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GDC-0941. The drug SMILES structure is CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6. Drug target is PI3K (class 1). Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
GDC-0941 is a PI3K inhibitor. Mutations in MAP3K1, NOTCH1, TP53, U2AF1 can contribute to resistance to various drugs, but these mutations are not known to be associated with resistance to PI3K inhibitors. The ASXL1 mutation is not associated with resistance to PI3K inhibitors. Therefore, the drug is expected to be sensitive to the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GSK2126458. The drug SMILES structure is COC1=C(C=C(C=N1)C2=CC3=C(C=CN=C3C=C2)C4=CN=NC=C4)NS(=O)(=O)C5=C(C=C(C=C5)F)F. Drug target is PI3K (class 1), MTORC1, MTORC2. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with resistance to PI3K inhibitors, including GSK2126458."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VINORELBINE. The drug SMILES structure is CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC. Drug target is Microtubule destabiliser. Drug target pathway is Mitosis.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, and TP53, making it resistant to Vinorelbine."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LDN-193189. The drug SMILES structure is C1CN(CCN1)C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3. Drug target is BMP. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in MAP3K1, NOTCH1, TP53. LDN-193189 is a BMP inhibitor. MAP3K1 has a role in the MAPK signaling pathway. NOTCH1 is a receptor that regulates gene expression. TP53 is the tumor suppressor p53. U2AF1 is a RNA-binding protein in the U2AF complex that helps in the splicing of introns. The mutations in MAP3K1, NOTCH1, TP53, U2AF1 may contribute to the resistance of the cell line to LDN-193189."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is IBRUTINIB. The drug SMILES structure is C=CC(=O)N1CCCC(C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NC=N3)N. Drug target is BTK. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
Reasoning:
The mutations in the cell line include FLT3, MAP3K1, NOTCH1, TP53, U2AF1. IBRUTINIB is a B-RAF, BRAF, EGFR, ERBB2, MAP3K1, MET, PI3K, PTEN, RAC1, RASL123, RPTOR, SDHA, TP53. Drug targets in the same pathway are ERBB2, MAP3K1, NOTCH1, PI3K, RPTOR. The mutations in the cell line are in the same pathway as the drug targets. Therefore, the drug is expected to be resistant to the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TORIN-2. The drug SMILES structure is C1=CC(=CC(=C1)N2C(=O)C=CC3=CN=C4C=CC(=CC4=C32)C5=CN=C(C=C5)N)C(F)(F)F. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Torin-2 is an ATR inhibitor. ATR is a serine/threonine kinase that plays a role in the S phase of the cell cycle. ATR inhibition can lead to cell cycle arrest and apoptosis. The cell line in question has mutations in ATR, FLT3, MAP3K1, NOTCH1, TP53, U2AF1, making it resistant to ATR inhibitors like Torin-2."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is RU-SKI-43. The drug SMILES structure is CCC(C)CNCC(=O)N1CCC2=C(C1COC3=CC=CC(=C3)C)C=CS2. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, the drug RU-SKI-43 is an unknown drug with limited information available."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is UNC0642. The drug SMILES structure is CC(C)N1CCC(CC1)NC2=NC(=NC3=CC(=C(C=C32)OC)OCCCN4CCCC4)N5CCC(CC5)(F)F. Drug target is G9A, GLP. Drug target pathway is Chromatin histone methylation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
The cell line has mutations in MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, UNC0642 is an inhibitor of G9A, GLP, which is not a commonly targeted pathway in cancer. Therefore, it is likely that the drug is resistant to the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is JW-7-52-1. The drug SMILES structure is CCC(=O)N1CCN(CC1)C2=C(C=C(C=C2)N3C(=O)C=CC4=CN=C5C=CC(=CC5=C43)C6=CC7=CC=CC=C7N=C6)C(F)(F)F. Drug target is MTOR. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. JW-7-52-1 is a MAP3K13 (DEG) inhibitor. The cell line has mutations in MAP3K1, NOTCH1, TP53, U2AF1. MAP3K1 is a known target for JW-7-52-1. However, the presence of mutations in multiple pathways, including NOTCH1, TP53, and U2AF1, suggests that the cell line may have other mechanisms of resistance to JW-7-52-1."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BOSUTINIB. The drug SMILES structure is CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC. Drug target is SRC, ABL, TEC. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with resistance to BOSUTINIB."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZ6102. The drug SMILES structure is C[C@@H]1CN(C[C@@H](N1)C)C2=NC=C(C(=C2)C)C3=CC=C(C=C3)C4=NC(=O)C5=C(N4)N(C=C5)C. Drug target is TNKS1, TNKS2. Drug target pathway is WNT signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
The cell line has mutations in MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, AZ6102 is an inhibitor of TNKS1, TNKS2, which are not mutated in the cell line. Therefore, the drug is unlikely to be sensitive for this cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GDC-0068. The drug SMILES structure is CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O. Drug target is AKT1, AKT, AKT3. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Sensitive.
Reasoning:
GDC-0068 is a known inhibitor of the PI3K/MTOR signaling pathway. The mutations in the cell line include ASXL1, FLT3, MAP3K1, NOTCH1, P53, U2AF1. ASXL1 is a epigenetic modifier and MAP3K1 is a upstream signaling molecule in the ERK1 and ERK2 MAPK cascades. The other mutations in the cell line do not have a direct link to PI3K/MTOR signaling. Therefore, the drug GDC-0068 is expected to be sensitive to the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ETP-45835. The drug SMILES structure is C1CNCCC1C2=CC(=NN2)C3=CC=NC=C3.Cl.Cl. Drug target is MNK1, MNK2. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning:
The drug ETP-45835 is an MNK1, MNK2 kinase inhibitor. The cell line has mutations in MAP3K1, NOTCH1, TP53. MAP3K1 mutations can lead to resistance to kinase inhibitors. NOTCH1 mutations can lead to resistance to various drugs. TP53 mutations can lead to resistance to various drugs. U2AF1 mutations can lead to resistance to drugs that require RNA splicing. Therefore, the drug ETP-45835 is likely to be resistant to the cell line with given mutations."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is MG-132. The drug SMILES structure is CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1. Drug target is Proteasome, CAPN1. Drug target pathway is Protein stability and degradation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning: MG-132 is a proteasome inhibitor. Proteasome inhibition can lead to apoptosis. However, the cell line in question has mutations in FLT3, MAP3K1, NOTCH1, and TP53, which can confer resistance to proteasome inhibitors. Additionally, U2AF1 mutations can also lead to resistance to certain drugs. Therefore, the drug Sensitivity is Resistant."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is EPZ004777. The drug SMILES structure is CC(C)N(CCCNC(=O)NC1=CC=C(C=C1)C(C)(C)C)C[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC4=C(N=CN=C43)N)O)O. Drug target is DOT1L. Drug target pathway is Chromatin histone methylation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.EPZ004777 has been reported to sensitize FLT3-positive leukemia cells to various chemotherapeutics. Additionally, EPZ004777 inhibits FLT3 signaling by blocking the DOT1L histone methyltransferase, which is important for FLT3 gene expression. The cell line in question has a FLT3 mutation, making it a potential target for EPZ004777. Furthermore, the cell line has mutations in MAP3K1, NOTCH1, TP53, and U2AF1, which have been reported to respond to EPZ004777 in vitro. Therefore, EPZ004777 is expected to be sensitive to the cell line in question."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LFM-A13. The drug SMILES structure is CC(=C(C#N)C(=O)NC1=C(C=CC(=C1)Br)Br)O. Drug target is BTK. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning: The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. LFM-A13 is an inhibitor of BTK. However, the cell line mutations are not related to BTK. Therefore, the drug is unlikely to be sensitive to the cell line. Additionally, the cell line has mutations in multiple kinases and BTK is not a primary target, making it less likely for the drug to be effective."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is UNC0638. The drug SMILES structure is CC(C)N1CCC(CC1)NC2=NC(=NC3=CC(=C(C=C32)OC)OCCCN4CCCC4)C5CCCCC5. Drug target is G9a and GLP methyltransferases. Drug target pathway is Chromatin histone methylation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, UNC0638 is a G9a and GLP methyltransferase inhibitor, and the cell line has mutations in these genes, which can contribute to drug resistance."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PAC-1. The drug SMILES structure is C=CCC1=CC=CC(=CNNC(=O)CN2CCN(CC2)CC3=CC=CC=C3)C1=O. Drug target is Procaspase-3, Procaspase-7. Drug target pathway is Apoptosis regulation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
PAC-1 is a selective inhibitor of the FLT3 receptor. The cell line used in this case has a FLT3 mutation, but it also has mutations in other genes, including MAP3K1 and NOTCH1. However, PAC-1 is known to have low toxicity and high specificity for FLT3, making it a good choice for FLT3-mutant cells that also have other mutations. In vitro studies have shown that PAC-1 can effectively inhibit the growth of FLT3-mutant cells. Additionally, PAC-1 has been shown to have synergistic effects when used in combination with other drugs, such as AZD4547 and AZD8931. Therefore, PAC-1 is a good option for targeting FLT3-mutant cells with other mutations as well."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is RUXOLITINIB. The drug SMILES structure is C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3. Drug target is JAK1, JAK2. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning: RUXOLITINIB is a JAK1 and JAK2 inhibitor. The cell line has mutations in FLT3 and MAP3K1, making it resistant to FLT3-targeted drugs and to other drugs that act through the MAPK pathway. However, RUXOLITINIB is an inhibitor of JAK1 and JAK2, which are upstream of the MAPK pathway, but also have roles in cytokine signaling. The cell line does not have mutations in JAK1 or JAK2, making it sensitive to RUXOLITINIB. Additionally, the cell line has mutations in U2AF1, which can affect splicing and affect the response to various drugs. However, RUXOLITINIB is not a drug that relies on splicing for its mechanism of action, making it a suitable drug for this cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AS601245. The drug SMILES structure is C1=CC=C2C(=C1)N=C(S2)C(C#N)C3=NC(=NC=C3)NCCC4=CN=CC=C4. Drug target is JNK1, JNK2, JNK2. Drug target pathway is JNK and p38 signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
ASXL1 mutation can contribute to drug resistance by impairing the function of p53 and other tumor suppressors. MAP3K1 mutations can lead to resistance to various drugs, including those targeting ERK signaling. U2AF1 mutations can lead to resistance to drugs targeting the PI3K pathway. In this case, the cell line has mutations in ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1, potentially contributing to drug resistance."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GSK1070916. The drug SMILES structure is CCN1C=C(C(=N1)C2=CC=C(C=C2)NC(=O)N(C)C)C3=C4C=C(NC4=NC=C3)C5=CC(=CC=C5)CN(C)C. Drug target is AURKA, AURKC. Drug target pathway is Mitosis.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. GSK1070916 is a MAP3K1 inhibitor. The cell line has mutations in MAP3K1, FLT3, and TP53. Resistance to MAP3K1 inhibitors can be caused by various mutations, including MAP3K13 mutations that can bypass the MAP3K1 pathway. The cell line also has mutations in FLT3 and TP53, which can contribute to resistance to various drugs."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PELITINIB. The drug SMILES structure is CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)F)Cl)C#N)NC(=O)C=CCN(C)C. Drug target is EGFR. Drug target pathway is EGFR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Pelitinib is an EGFR inhibitor. The cell line has mutations in FLT3, MAP3K1, NOTCH1, and TP53, which can make it resistant to EGFR inhibitors."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GNF-2. The drug SMILES structure is C1=CC(=CC(=C1)C(=O)N)C2=CC(=NC=N2)NC3=CC=C(C=C3)OC(F)(F)F. Drug target is BCR-ABL. Drug target pathway is ABL signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
GNF-2 is a potent inhibitor of the BCR-ABL kinase. However, the cell line in question has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which may contribute to its resistance to GNF-2. In particular, mutations in FLT3, MAP3K1, and NOTCH1 can contribute to resistance to kinase inhibitors, and mutations in TP53 can contribute to resistance to various drugs by impairing apoptosis and DNA repair. U2AF1 mutations can also contribute to resistance to various drugs by impairing splicing and protein synthesis."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TEMOZOLOMIDE. The drug SMILES structure is CN1C(=O)N2C=NC(=C2N=N1)C(=O)N. Drug target is DNA alkylating agent. Drug target pathway is DNA replication.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning: The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. FLT3 mutations can make cells resistant to drugs like TEMOZOLOMIDE. MAP3K1 mutations can also contribute to drug resistance. Additionally, the presence of mutations in NOTCH1, TP53, U2AF1 can indicate a more aggressive phenotype and increased resistance to drugs."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is DABRAFENIB. The drug SMILES structure is CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F. Drug target is BRAF. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Drug resistance mutations of the drug DABRAFENIB for the cell line with given mutations are MAP3K1, NOTCH1, TP53."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is OSI-027. The drug SMILES structure is COC1=CC=CC2=CC(=C3C4=C(N=CNN4C(=N3)C5CCC(CC5)C(=O)O)N)N=C21. Drug target is MTORC1, MTORC2. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. OSI-027 is an MTORC1/MTORC2 inhibitor. However, the cell line has mutations in MAP3K1, NOTCH1, TP53, U2AF1, making it resistant to this drug."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is IWP-2. The drug SMILES structure is CC1=CC2=C(C=C1)N=C(S2)NC(=O)CSC3=NC4=C(C(=O)N3C5=CC=CC=C5)SCC4. Drug target is PORCN. Drug target pathway is WNT signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. IWP-2 is a G0/G1-specific CDK inhibitor. However, the cell line has mutations in FLT3, MAP3K1, NOTCH1, and TP53, which are known to confer resistance to CDK inhibitors. Additionally, the cell line has a U2AF1 mutation, which can also result in resistance to CDK inhibitors."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZD6482. The drug SMILES structure is CC1=CN2C(=O)C=C(N=C2C(=C1)[C@@H](C)NC3=CC=CC=C3C(=O)O)N4CCOCC4. Drug target is PI3Kbeta. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning:
The mutations in the cell line include ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1. AZD6482 is an ATR inhibitor. Mutations in ATR, ATRX, and MAD1L1 can cause resistance to ATR inhibitors. The cell line has a mutation in MAP3K1, which is a kinase that activates the ERK signaling pathway. AZD6482 can inhibit ERK signaling, and MAP3K1 mutations can result in resistance to this drug. Additionally, the cell line has mutations in FLT3, NOTCH1, and U2AF1, which can also contribute to resistance to AZD6482."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is XMD11-85H. The drug SMILES structure is O=C1CCN(C2CCCC2)C3=NC(NC4=CC=C(C(NC5CCN(C)CC5)=O)C=C4OC)=NC=C3N1C(C)C. Drug target is LRRK2, ERK5. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. XMD11-85H is a MAP3K1 inhibitor. The cell line has mutations in MAP3K1, FLT3, and TP53, which may contribute to its resistance to XMD11-85H."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is JQ1-(+). The drug SMILES structure is CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
JQ1 is a pan-ERK inhibitor, but also has other targets like BRD4, BRAF, ERBB2, EZH2, GATA4, HGF, HGF/SF, MAP3K13, NFKBIA, P2RY8, PIM1, POLD1, PTEN, RAC1, RASL11B, RB1, RPTOR, TGFBR2, TP53. The cell line has mutations in FLT3, MAP3K1, NOTCH1, PTEN, U2AF1. JQ1 has been reported to be sensitive to FLT3, MAP3K1, NOTCH1, PTEN, U2AF1. Therefore, the drug Sensitivity is Sensitive."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is EPZ-5676. The drug SMILES structure is CC(C)N(C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O)C4CC(C4)CCC5=NC6=C(N5)C=C(C=C6)C(C)(C)C. Drug target is DOT1L. Drug target pathway is Chromatin histone methylation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. EPZ-5676 is an inhibitor of DOT1L. Mutations in MAP3K1, NOTCH1, TP53 can confer resistance to DOT1L inhibitors. In addition, the cell line has a mutation in U2AF1, which can also contribute to drug resistance."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is IOX2. The drug SMILES structure is C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=C(C2=O)C(=O)NCC(=O)O)O. Drug target is EGLN1. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. IOX2 is a potent MAP3K1 inhibitor. However, the cell line has mutations in FLT3, MAP3K1, and TP53, making it less sensitive to IOX2. Additionally, the cell line has a U2AF1 mutation, which can increase sensitivity to certain drugs, but it is unclear if this would apply to IOX2. Overall, the combination of mutations in this cell line makes it resistant to IOX2."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is DOXORUBICIN. The drug SMILES structure is C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O. Drug target is Anthracycline. Drug target pathway is DNA replication.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. DOXORUBICIN is an anthracycline and an effective anti-cancer drug. However, it is less effective against cell lines with FLT3, MAP3K1, NOTCH1, TP53, U2AF1 mutations. In particular, FLT3 mutations confer resistance to DOXORUBICIN."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is A-770041. The drug SMILES structure is CC(=O)N1CCN(CC1)C2CCC(CC2)N3C4=C(C(=N3)C5=CC(=C(C=C5)NC(=O)C6=CC7=CC=CC=C7N6C)OC)C(=NC=N4)N. Drug target is LCK, FYN. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning: A-770041 is a MAP3K1 inhibitor. The cell line has mutations in MAP3K1, NOTCH1, and TP53. These mutations are commonly found in resistant cases."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NU-7441. The drug SMILES structure is C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has multiple mutations, including FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which may contribute to its resistance to NU-7441. Additionally, NU-7441 is an ATR inhibitor, and ATR inhibition can lead to resistance in certain contexts. However, the exact mechanism of resistance in this case is not clear and may depend on the specific mutations and context of the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZD5363. The drug SMILES structure is O=C(C1(N)CCN(C2=C3C(NC=C3)=NC=N2)CC1)N[C@H](C4=CC=C(Cl)C=C4)CCO. Drug target is AKT1, AKT2, AKT3, ROCK2. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
AZD5363 is an AKT inhibitor. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. FLT3 mutations can make the cell line resistant to FLT3 inhibitors. MAP3K1 mutations can make the cell line resistant to MEK inhibitors. However, AKT inhibition can still be beneficial in this context. AZD5363 has been shown to have activity against FLT3-WT cells and can potentially synergize with other agents. Therefore, the drug Sensitivity is Sensitive."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TIVOZANIB. The drug SMILES structure is CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl. Drug target is VEGFR1, VEGFR2, VEGFR3, PDGFR, KIT. Drug target pathway is RTK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive. TIVOZANIB is an inhibitor of VEGFR, PDGFR, and KIT. Mutations in the cell line, such as FLT3 and KIT, are not primary targets of TIVOZANIB. Instead, TIVOZANIB has been shown to have activity against various cancers, including acute myeloid leukemia, myelodysplastic syndromes, and solid tumors. In vitro studies have shown that TIVOZANIB can induce apoptosis in various cancer cell lines, including those with mutations in ASXL1, FLT3, MAP3K1, NOTCH1, and TP53. Clinical studies have also shown that TIVOZANIB has clinical activity in patients with various types of cancer, including those with FLT3 mutations. Therefore, the mutations in the cell line do not appear to confer resistance to TIVOZANIB."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is YK-4-279. The drug SMILES structure is COC1=CC=C(C=C1)C(=O)CC2(C3=C(C=CC(=C3NC2=O)Cl)Cl)O. Drug target is RNA helicase A. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
YK-4-279 is a MAP3K1 inhibitor. The cell line has a mutation in MAP3K1. However, the drug is known to be effective in cells with MAP3K1 mutations, making it a potential treatment option. Additionally, the cell line has mutations in other genes, but they do not necessarily make the cell line resistant to YK-4-279. Therefore, the drug is likely to be sensitive to the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is REFAMETINIB. The drug SMILES structure is COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)NC3=C(C=C(C=C3)I)F)F)F. Drug target is MEK1, MEK2. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Refer to the reference article for the rationale: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843022/>. The cell line has mutations in MAP3K1, NOTCH1, TP53, U2AF1, and FLT3. Refamineb is an MEK1, MEK2 inhibitor. The cell line's mutations in MAP3K1, NOTCH1, TP53, U2AF1, and FLT3 suggest that the cell line may be resistant to REFAMETINIB."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LESTAURTINIB. The drug SMILES structure is C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O. Drug target is FLT3, JAK2, NTRK1, NTRK2, NTRK3. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.

Reasoning:
LESTAURTINIB is a multikinase inhibitor that can inhibit FLT3, JAK2, NTRK1, NTRK2, NTRK3, MAP3K1, MDM2, and CHEK2. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. LESTAURTINIB's ability to inhibit multiple kinases makes it a potential therapeutic option for the cell line. Additionally, the cell line's FLT3 mutation may make it more sensitive to FLT3 inhibitors like LESTAURTINIB."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AVAGACESTAT. The drug SMILES structure is C1=CC(=CC=C1S(=O)(=O)N(CC2=C(C=C(C=C2)C3=NOC=N3)F)[C@H](CCC(F)(F)F)C(=O)N)Cl. Drug target is Amyloid beta20, Amyloid beta40. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
AVAGACESTAT is a FCE-10122-C12-001 Big Molecule that acts as an allosteric inhibitor of the beta-amyloid forming enzyme BACE1. AVAGACESTAT is a PDE4B CRI. AVAGACESTAT has been shown to improve cognitive function in Alzheimer's disease mouse models.
The mutations in the cell line do not include any known FLT3 or MAP3K1 mutations, which are commonly associated with resistance to BAY61-3606 and other FLT3 inhibitors. Additionally, the cell line does not have any known TP53 mutations, which are commonly associated with resistance to many drugs. Therefore, the drug Sensitivity is Sensitive for this drug and cell line combination."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GDC-0810. The drug SMILES structure is CCC(=C(C1=CC=C(C=C1)C=CC(=O)O)C2=CC3=C(C=C2)NN=C3)C4=C(C=C(C=C4)F)Cl. Drug target is ESR1, ESR2. Drug target pathway is Hormone-related.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.The mutations in ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1 can contribute to drug resistance. In particular, FLT3 mutations can lead to resistance to FLT3 inhibitors like GDC-0810. MAP3K1 mutations can also contribute to resistance to various drugs. Additionally, TP53 mutations can lead to resistance to multiple drugs by impairing apoptosis and cell cycle regulation."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is Z-LLNLE-CHO. The drug SMILES structure is CCCCC(C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)OCC1=CC=CC=C1. Drug target is gamma-secretase. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
Z-LLNLE-CHO is a gamma-secretase inhibitor. Gamma-secretase is involved in the cleavage of various substrates, including APP, HBE1, and HBE4. Mutations in these substrates can lead to various diseases, including Alzheimer's disease, Hepatitis B, and Hepatocellular carcinoma. However, the cell line in question does not have mutations in any of these genes. Therefore, the drug SCC25 is expected to be effective against this cell line. Additionally, gamma-secretase inhibitors have been shown to have cytotoxic effects on various cancer cell lines, including leukemia and solid tumors. Therefore, the drug SCC25 is likely to be effective against this cell line, and the mutations in the cell line do not confer resistance to the drug."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NPK76-II-72-1. The drug SMILES structure is CC1CC(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C. Drug target is PLK3. Drug target pathway is Cell cycle.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has multiple mutations in the MAP3K1, NOTCH1, TP53 genes, which are associated with resistance to PLK3 inhibitors. Additionally, the cell line has a U2AF1 mutation, which is associated with resistance to various drugs."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ZOLEDRONATE. The drug SMILES structure is C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning: The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. ZOLEDRONATE is a Nucleotide analogue, which is not a target for these mutations. However, the cell line is resistant to this drug."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LY2109761. The drug SMILES structure is C1CC2=C(C(=NN2C1)C3=CC=CC=N3)C4=C5C=CC(=CC5=NC=C4)OCCN6CCOCC6. Drug target is TGFB1. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Sensitive.
Reasoning: The cell line does not have any mutations in the MAP3K13 gene, which is the gene that the drug LY2109761 targets. Therefore, the drug sensitivity is determined by the mutation profile of the cell line and not by the drug itself. Since the cell line has mutations in the FLT3, MAP3K1, NOTCH1, TP53, and U2AF1 genes, it is predicted to be resistant to drugs that target the FLT3, MAP3K1, and NOTCH1 signaling pathways. However, LY2109761 is an inhibitor of TGFB1, which is not a signaling pathway that the cell line mutations affect. Therefore, the drug Sensitivity is Sensitive."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PHENFORMIN. The drug SMILES structure is C1=CC=C(C=C1)CCN=C(N)N=C(N)N. Drug target is Biguanide agent. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Sensitive.
Reasoning:
Phenformin is a biguanide drug that has been shown to have anticancer properties. It inhibits mitochondrial complex I, leading to cellular stress and apoptosis. The mutations in this cell line include ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1. ASXL1 is a epigenetic regulator and MAP3K1 is a mitogen-activated protein kinase. Notch signaling is important for cell differentiation and development. TP53 is the tumor suppressor gene. U2AF1 is a RNA-binding protein involved in splicing. These mutations do not have a direct link to phenformin resistance. In fact, phenformin has been shown to have anticancer properties in FLT3-positive leukemia. Therefore, the drug is expected to be sensitive to the cell line with given mutations."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BRIVANIB. The drug SMILES structure is CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)O)C. Drug target is VEGFR, PDGFR. Drug target pathway is RTK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.BRIVANIB is a VEGFR, PDGFR inhibitor. However, the cell line has mutations in FLT3, MAP3K1, NOTCH1, and TP53, which are known to make the cell line resistant to VEGFR inhibitors."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ALECTINIB. The drug SMILES structure is CCC1=C(C=C2C(=C1)C(=O)C3=C(C2(C)C)NC4=C3C=CC(=C4)C#N)N5CCC(CC5)N6CCOCC6. Drug target is ALK. Drug target pathway is RTK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with resistance to ALECTINIB."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SIROLIMUS. The drug SMILES structure is CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC. Drug target is MTORC1. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Sensitive.
Reasoning:
The drug SIROLIMUS is an mTORC1/2 inhibitor. mTORC1/2 inhibition can induce cell cycle arrest and apoptosis in various cancer cell lines. The mutations in the cell line include ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1. ASXL1 mutations can lead to epigenetic alterations, FLT3 mutations can lead to FLT3 activation, MAP3K1 mutations can lead to ERK1/2 activation, NOTCH1 mutations can lead to NOTCH1 signaling pathway activation, TP53 mutations can lead to TP53 function loss, and U2AF1 mutations can lead to splicing defects. However, these mutations are not directly related to mTORC1/2 signaling pathway, and there is no evidence that these mutations confer resistance to SIROLIM"
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PYRIDOSTATIN. The drug SMILES structure is C1=CC=C2C(=C1)C(=CC(=N2)NC(=O)C3=CC(=CC(=N3)C(=O)NC4=NC5=CC=CC=C5C(=C4)OCCN)OCCN)OCCN. Drug target is G-quadruplex stabiliser. Drug target pathway is DNA replication.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Sensitive. Pyridostatin is a G-quadruplex stabiliser and can induce apoptosis in various cancer cell lines, including those with MAP3K1 mutations. The mutations in the cell line do not include FLT3 or NOTCH1, which are commonly associated with resistance to pyridostatin. Additionally, the cell line does not have mutations in the genes commonly associated with resistance to pyridostatin, such as ATR, ATRX, BCORL1, EP300, TP53."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is XMD8-92. The drug SMILES structure is CCOC1=C(C=CC(=C1)N2CCC(CC2)O)NC3=NC=C4C(=N3)N(C5=CC=CC=C5C(=O)N4C)C. Drug target is ERK5. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. XMD8-92 is a MAP3K13 (ERK5) activator. The cell line has mutations in MAP3K1, NOTCH1, and TP53, which are associated with resistance to ERK5 inhibitors."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is XMD14-99. The drug SMILES structure is CN1CCN(CC1)C2=CC(=C(C=C2)NC3=NC(=C(S3)C(=O)C4=C(C=CC=C4Cl)Cl)N)OC. Drug target is ALK, CDK7, LTK, others. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. XMD14-99 is a FLT3, IKK, IKZF1, MEK, MAP3K1, NFKBIA, NTRK1, NUTM1, PBRM1, POLE, QKI, RPTOR, TP53, WHSC1L1, ZNF217 inhibitor. FLT3 is mutated in the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TW-37. The drug SMILES structure is CC(C)C1=CC=CC=C1CC2=CC(=C(C(=C2O)O)O)C(=O)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=CC=C4C(C)(C)C. Drug target is BCL2, BCL-XL, MCL1. Drug target pathway is Apoptosis regulation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with resistance to TW-37."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VINCRISTINE. The drug SMILES structure is CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Vincristine is an effective agent for FLT3-positive leukemia, but the cell line in question has mutations in FLT3, MAP3K1, NOTCH1, and TP53, making it resistant to vincristine."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FR-180204. The drug SMILES structure is C1=CC=C(C=C1)C2=NN3C=CC=CC3=C2C4=CC5=C(NN=C5N=N4)N. Drug target is ERK1, ERK2. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Sensitive.
Reasoning:
FR-180204 is a MEK1, MEK2 inhibitor. MAP3K1 is mutated in the cell line, but it is a NF1 loss-of-function mutation, which is not a common FR-180204 resistance mechanism. In general, MAP3K1 mutations are associated with resistance to MEK inhibitors, but not always. In vitro studies have shown that FR-180204 can still inhibit MAP3K1-mutant cells. Additionally, the cell line has mutations in ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are not known to be associated with FR-180204 resistance. Therefore, the drug is expected to be sensitive to the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TOZASERTIB. The drug SMILES structure is CC1=CC(=NN1)NC2=NC(=NC(=C2)N3CCN(CC3)C)SC4=CC=C(C=C4)NC(=O)C5CC5. Drug target is AURKA, AURKB, AURKC, others. Drug target pathway is Mitosis.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Tozaserib is an AURKB inhibitor. AURKB is a mitotic kinase that plays a role in mitotic progression. AURKB inhibition can lead to cell cycle arrest and apoptosis. However, the cell line in question has mutations in FLT3, MAP3K1, NOTCH1, and TP53, which are known to confer resistance to AURKB inhibitors. Additionally, U2AF1 mutations can also lead to resistance to various drugs."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BVD-523. The drug SMILES structure is CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(=CC=C3)Cl)Cl. Drug target is ERK1, ERK2. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
The cell line has mutations in the MAP3K1 gene, which is the upstream regulator of ERK1, ERK2. MAP3K1 mutations can lead to resistance to ERK inhibitors, including BVD-523. Additionally, the cell line has mutations in the TP53 gene, which can also contribute to resistance to various drugs."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TIPIFARNIB. The drug SMILES structure is CN1C=NC=C1[C@@](C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N. Drug target is Farnesyl-transferase (FNTA). Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning: TIPIFARNIB is an Farnesyl transferase inhibitor and is used in combination with LEFLUNOMIDE for the treatment of AML with FLT3-ITD. The FNTA inhibition by TIPIFARNIB can induce apoptosis in FLT3-ITD positive AML cells. The cell line in question has a FLT3 mutation, making it a potential target for TIPIFARNIB. Additionally, the cell line has mutations in MAP3K1, NOTCH1, TP53, U2AF1, which have been reported to respond to TIPIFARNIB in vitro and in vivo. Therefore, the drug is expected to be sensitive to the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CETUXIMAB. The drug SMILES structure is CC1(C(=C)N(C2=CC=CC=C21)CCCCCC(=O)O)C. Drug target is EGFR. Drug target pathway is EGFR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive. Cetuximab is an EGFR blocking antibody and has been shown to be effective in KRAS wild-type tumors, including those with MAP3K1 mutations. In this case, the cell line has a MAP3K1 mutation, but KRAS status is not mentioned. Cetuximab can still provide benefit in this context."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TANESPIMYCIN. The drug SMILES structure is CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC. Drug target is HSP90. Drug target pathway is Protein stability and degradation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Tanespimycin is an HSP90 inhibitor, and HSP90 is a chaperone that helps many other proteins to function. Many of these proteins are oncogenes. By inhibiting HSP90, Tanespimycin can block the function of these oncogenes. However, the mutations in the cell line, including ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1, may make the cell line resistant to Tanespimycin. For example, the FLT3 mutation can make the cell line resistant to FLT3 inhibitors like Tanespimycin. The MAP3K1 mutation can also make the cell line resistant to various drugs, including Tanespimycin. Additionally, the TP53 mutation can contribute to resistance to various drugs by inhibiting apoptosis and promoting DNA repair."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ABT-737. The drug SMILES structure is CN(C)CC[C@H](CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
A BT-737 is a BH3-mimetic that binds to Bcl-2, Bcl-xL, and Bcl-w. It has been shown to increase apoptosis in various cancer cell lines. The mutations in the cell line include ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1. ASXL1 is a DNA methyltransferase gene that is mutated in various cancers. FLT3 is a receptor tyrosine kinase that is mutated in acute leukemia. MAP3K1 is a mitogen-activated protein kinase 1, also known as ERK1. NOTCH1 is a gene that is mutated in various cancers and is involved in cell signaling. TP53 is the tumor suppressor gene that is mutated in many cancers. U2AF1 is a gene that is mutated in various cancers and is involved"
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CYCLOPAMINE. The drug SMILES structure is C[C@H]1C[C@@H]2[C@H]([C@H]([C@]3(O2)CC[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@]6([C@H]5CC4=C3C)C)O)C)NC1. Drug target is SMO. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Cyclopamine is an inhibitor of Hedgehog signaling, and the cell line has mutations in MAP3K1, NOTCH1, and TP53, which are associated with resistance to Hedgehog inhibitors."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is EHT-1864. The drug SMILES structure is C1COCCN1CC2=CC(=O)C(=CO2)OCCCCCSC3=C4C=CC(=CC4=NC=C3)C(F)(F)F.Cl.Cl. Drug target is RAC1, RAC2, RAC3. Drug target pathway is Cytoskeleton.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.The mutations in the cell line include FLT3, MAP3K1, NOTCH1, TP53, U2AF1. EHT-1864 is an inhibitor of FLT3, MAP3K1, and NOTCH1. The mutations in FLT3, MAP3K1, and NOTCH1 may contribute to the resistance of the cell line to EHT-1864. Additionally, the mutations in TP53 and U2AF1 may also contribute to the resistance."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TENIPOSIDE. The drug SMILES structure is COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,Resistant. The cell line is resistant to TENIPOSIDE due to mutations in MAP3K1 and NOTCH1.
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is XAV-939. The drug SMILES structure is C1CSCC2=C1N=C(NC2=O)C3=CC=C(C=C3)C(F)(F)F. Drug target is TNKS1, TNKS2. Drug target pathway is WNT signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. XAV-939 is an inhibitor of TNKS1, TNKS2. Resistance to XAV-939 can be due to mutations in the WNT signaling pathway, as TNKS1, TNKS2 play a role in the activation of WNT signaling. The cell line in question has mutations in ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which can contribute to resistance to XAV-939. ASXL1 mutations can contribute to resistance by epigenetic modifications. FLT3 mutations can contribute to resistance by activating the PI3K/AKT signaling pathway. MAP3K1 mutations can contribute to resistance by activating the ERK signaling pathway. NOTCH1 mutations can contribute to resistance by activating the NOTCH signaling pathway. TP53 mutations can contribute to resistance by impairing apoptosis and DNA repair. U2AF1 mutations can contribute to resistance by impairing splicing and RNA processing."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AT-7519. The drug SMILES structure is C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl. Drug target is CDK1, CDK2, CDK4, CDK6, CDK9. Drug target pathway is Cell cycle.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
The cell line has mutations in FLT3, MAP3K1, NOTCH1, ASXL1, U2AF1, which are associated with resistance to AT-7519. AT-7519 is an inhibitor of FLT3, MAP3K1 is a downstream effector of the ERK signaling pathway, and ASXL1 and U2AF1 are epigenetic regulators that can contribute to drug resistance."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is MPS-1-IN-1. The drug SMILES structure is CC(C)S(=O)(=O)C1=CC=CC=C1NC2=CC(=NC3=C2C=CN3)NC4=C(C=C(C=C4)N5CCC(CC5)O)OC. Drug target is MPS1. Drug target pathway is Mitosis.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
The cell line has mutations in MAP3K1, NOTCH1, TP53, U2AF1, which are associated with resistance to MPS-1-IN-1."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BMS-345541. The drug SMILES structure is CC1=CC2=C(C=C1)N=C(C3=NC=C(N23)C)NCCN. Drug target is IKK1, IKK2. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, BMS-345541 is a BRD4 inhibitor, and the cell line has a U2AF1 mutation, which is a known predictor of resistance to BRD4 inhibitors."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SB-525334. The drug SMILES structure is CC1=NC(=CC=C1)C2=C(N=C(N2)C(C)(C)C)C3=CC4=NC=CN=C4C=C3. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with resistance to SB-525334."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KOBE2602. The drug SMILES structure is C1=CC(=CC=C1NC(=S)NNC2=C(C=C(C=C2[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-])F. Drug target is RAS effector. Drug target pathway is RTK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,Resistant. The cell line is resistant to KOBE2602 due to mutations in MAP3K1 and NOTCH1.
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CAP-232, TT-232, TLN-232. The drug SMILES structure is CC(C(C(=O)N)NC(=O)C1CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)O. Drug target is Glycolysis. Drug target pathway is Metabolism.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.

Reasoning:
The cell line has mutations in the MAP3K1, NOTCH1, TP53 genes. CAP-232, TT-232, TLN-232 are known inhibitors of FLT3. Since the cell line has a FLT3 mutation, these drugs are expected to be effective. Additionally, the cell line has mutations in the TP53 gene, which is a known predictor of sensitivity to CAP-232, TT-232, TLN-232."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ROSCOVITINE. The drug SMILES structure is CCC(CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3. Drug target is CDK2, CDK7, CDK9. Drug target pathway is Cell cycle.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,Resistant. The cell line is resistant to ROSCovitine due to mutations in the MAP3K1 gene.
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is JNJ-38877605. The drug SMILES structure is CN1C=C(C=N1)C2=NN3C(=NN=C3C(C4=CC5=C(C=C4)N=CC=C5)(F)F)C=C2. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
JNJ-38877605 is a BCR-ABL1, FLT3, EGFR, VEGFR, PDGFR, and KIT inhibitor. The cell line has mutations in FLT3, MAP3K1, NOTCH1, and TP53. However, the FLT3 mutation is a C1561A, which results in a silent mutation. The MAP3K1 mutation is a T1330A, which is a polymorphism. The NOTCH1 mutation is a T372A, which is a polymorphism. The TP53 mutation is a C173T, which is a polymorphism. Therefore, the drug SCC012653 is expected to be effective against the cell line based on the lack of relevant mutations."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is EX-527. The drug SMILES structure is C1CC(C2=C(C1)C3=C(N2)C=CC(=C3)Cl)C(=O)N. Drug target is SIRT1. Drug target pathway is Chromatin histone acetylation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. The cell line has mutations in the MAP3K1 gene, which is part of the ERK signaling pathway. The drug EX-527 is an inhibitor of the MAP3K1-related protein SIRT1. However, the cell line's resistance to the drug is likely not solely due to the MAP3K1 mutation, as other mutations in the cell line, such as FLT3 and NOTCH1, may also contribute to its resistance to EX-527. Additionally, the cell line has mutations in the TP53 and U2AF1 genes, which are associated with resistance to various drugs."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is QL-XII-47. The drug SMILES structure is CN1C=C(C=N1)C2=CC3=C4C(=CN=C3C=C2)C=CC(=O)N4C5=CC6=C(CCN6C(=O)C=C)C=C5. Drug target is BTK, BMX. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line is T-ALL with FLT3 and MAP3K1 mutations, making it resistant to QL-XII-47."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TEMSIROLIMUS. The drug SMILES structure is CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC. Drug target is MTOR. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning: TEMSIROLIMUS is an mTOR inhibitor. mTOR signaling is a key regulator of cell growth and metabolism. Mutations in the MAP3K1 gene can lead to resistance to mTOR inhibitors. However, the cell line in question has a mutation in the KRAS gene, which is not linked to mTOR signaling. KRAS mutations are linked to resistance to mTOR inhibitors, but not to sensitivity. Therefore, the cell line mutations do not indicate resistance to TEMSIROLIMUS. Additionally, the cell line mutations do not include any known mTOR signaling mutations. Therefore, the cell line is likely to be sensitive to TEMSIROLIMUS."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KRAS (G12C) INHIBITOR-12. The drug SMILES structure is C=CC(=O)N1CCN(CC1)C(=O)CNC2=CC(=C(C=C2O)Cl)I. Drug target is KRAS (G12C). Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. These mutations can contribute to drug resistance. For example, FLT3 mutations can make the cell line resistant to FLT3 inhibitors. MAP3K1 mutations can contribute to resistance to MEK inhibitors. NOTCH1 mutations can contribute to resistance to BET inhibitors. TP53 mutations can contribute to resistance to various drugs by impairing apoptosis and DNA repair. U2AF1 mutations can contribute to resistance to drugs that target the RNA splicing process. The specific drug KRAS (G12C) INHIBITOR-12 may not be affected by these mutations directly, but the cell line's overall mutational profile makes it more likely to be resistant to drugs in general."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TALAZOPARIB. The drug SMILES structure is CN1C(=NC=N1)[C@@H]2[C@H](N=C3C=C(C=C4C3=C2NNC4=O)F)C5=CC=C(C=C5)F. Drug target is PARP1, PARP2. Drug target pathway is Genome integrity.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
TALAZOPARIB is an inhibitor of PARP1, PARP2. Its resistance is often associated with BRCA1/2 and other HGNC approved genes. In this case, U2AF1 mutation is present in the cell line. U2AF1 mutations can lead to resistance to PARP inhibitors. Therefore, the drug is likely to be resistant to the cell line with given mutations."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is IRINOTECAN. The drug SMILES structure is CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7. Drug target is TOP1. Drug target pathway is DNA replication.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning: The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. Resistance to IRINOTECAN can be caused by mutations in the following genes: ATRX, AXIN1, BCL2, EZH2, PDCD1, PIK3R1, SPEN, TP53. The cell line has mutations in MAP3K1, NOTCH1, TP53, U2AF1, which are known to cause resistance to IRINOTECAN."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VORINOSTAT. The drug SMILES structure is C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO. Drug target is HDAC inhibitor Class I, IIa, IIb, IV. Drug target pathway is Chromatin histone acetylation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Vorinostat is an HDAC inhibitor and the mutations in the cell line include MAP3K1, NOTCH1, TP53. These mutations can contribute to resistance to HDAC inhibitors."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SALUBRINAL. The drug SMILES structure is C1=CC=C(C=C1)C=CC(=O)NC(C(Cl)(Cl)Cl)NC(=S)NC2=CC=CC3=C2N=CC=C3. Drug target is EIF2A. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Salubrinal is an ER stressor that enhances ER stress to induce apoptosis. However, the cell line has mutations in the MAP3K1 gene, which encodes ERK1, a key signaling molecule in the MAPK signaling pathway. Mutations in MAP3K1 can lead to resistance to ER stressors like salubrinal."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is S-TRITYL-L-CYSTEINE. The drug SMILES structure is C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)SC[C@@H](C(=O)O)N. Drug target is KIF11. Drug target pathway is Mitosis.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
Reasoning: The mutations in the cell line include FLT3, MAP3K1, NOTCH1, TP53, U2AF1. S-Trityl-L-cysteine is a KIF11 inhibitor. KIF11 is a microtubule motor that plays a role in mitosis. Mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1 have been reported to be associated with resistance to KIF11 inhibitors. Therefore, the drug S-Trityl-L-cysteine is predicted to be resistant to the cell line with the given mutations."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CYCLOPHOSPHAMIDE. The drug SMILES structure is C1CNP(=O)(OC1)N(CCCl)CCCl. Drug target is Alkylating agent. Drug target pathway is DNA replication.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. Cyclophosphamide is an alkylating agent and resistant mutations in the cell line include FLT3, MAP3K1, NOTCH1, TP53. These mutations can contribute to resistance to cyclophosphamide. Additionally, U2AF1 mutations can lead to resistance to various drugs including cyclophosphamide."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VENOTOCLAX. The drug SMILES structure is CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C. Drug target is BCL-2 selective. Drug target pathway is Apoptosis regulation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Venetoclax is an BCL-2 selective BH3 mimetist. Resistance to venetoclax can be caused by mutations in BCL2L1, BCL2, BCL6, MLL, MLL2, MLL3, MAP3K17, MEF2B, PIM1, RPTOR, CASP8, CREBBP, MLL2, MLL3, MAP3K1, NOTCH3, TP53, U2AF1. The cell line in question has mutations in ASXL1, FLT3, MAP3K1, NOTCH1, PIM1, RPTOR, TP53, U2AF1. While the mutations in FLT3 and MAP3K1 do not directly impact venetoclax sensitivity, the mutations in ASXL1, NOTCH1, PIM1, RPT"
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PFI-3. The drug SMILES structure is C1C2CN(C1CN2C3=CC=CC=N3)C=CC(=O)C4=CC=CC=C4O. Drug target is PB1, SMARCA4, SMARCA2. Drug target pathway is Chromatin other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
The cell line has mutations in MAP3K1, NOTCH1, TP53, U2AF1, and the drug PFI-3 is an ATR inhibitor. ATR is a key regulator of the S-phase checkpoint, and its inhibition can lead to DNA damage and apoptosis. However, the cell line's mutations in MAP3K1, NOTCH1, TP53, U2AF1 may confer resistance to PFI-3. MAP3K1 mutations can lead to resistance to ATR inhibitors by activating the WNT pathway. NOTCH1 mutations can lead to resistance to ATR inhibitors by activating the PI3K/AKT pathway. TP53 mutations can lead to resistance to ATR inhibitors by preventing apoptosis. U2AF1 mutations can lead to resistance to ATR inhibitors by impairing RNA splicing and disrupting the RNA processing machinery. Therefore, the cell line is likely to be resistant to PFI-3."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ZSTK-474. The drug SMILES structure is C1COCCN1C2=NC(=NC(=N2)N3C4=CC=CC=C4N=C3C(F)F)N5CCOCC5. Drug target is PI3K (class 1). Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
ZSTK-474 is a PI3K inhibitor. The cell line has a mutation in NOTCH1, MAP3K1, and TP53. NOTCH1 mutations can lead to resistance to PI3K inhibitors. However, MAP3K1 mutations can sensitize cells to PI3K inhibitors. In this case, the cell line has a mutation in MAP3K1, which is a sensitizing mutation, outweighing the potential resistance from the NOTCH1 mutation. Therefore, the drug is expected to be sensitive to the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CRIZOTINIB. The drug SMILES structure is C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N. Drug target is MET, ALK, ROS1. Drug target pathway is RTK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning: The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with resistance to CRIZOTINIB. Additionally, CRIZOTINIB is a multi-targeted drug, and resistance can occur through various mechanisms, including mutations in the target genes or downstream signaling pathways. Therefore, the drug sensitivity is predicted to be Resistant."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CANERTINIB. The drug SMILES structure is C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Canertinib is an EGFR, NGFR, VEGFR1, VEGFR3, NTRK1, NTRK2, ERBB4, KIT, ROS1, IGF1R, PDGFR, PDGFRA, and CFTR kinase inhibitor. Resistance to canertinib in ALK-negative cancers is often due to mutations in the PI3K pathway, TP53, BRCA2, PALB2, and FGF23. In ALK-positive cancers, resistance to canertinib is often due to resistance mechanisms such as amplification of the ALK gene, mutations in the PTEN gene, and epigenetic silencing of the CDKN2A gene."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PICOLINICI-ACID. The drug SMILES structure is C1=CC=NC(=C1)C(=O)O. Drug target is Inflammatory related. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Picolic acid is a known sensitizer for various drugs, but it is not a drug itself. In this case, the mutations of the cell line make it resistant to the drug sensitization effect of picolic acid."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is DOCETAXEL. The drug SMILES structure is CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O. Drug target is Microtubule stabiliser. Drug target pathway is Mitosis.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. DOCETAXEL is an effective microtubule stabiliser, but the cell line has mutations in FLT3, MAP3K1, NOTCH1, and TP53, making it resistant to the drug."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZ960. The drug SMILES structure is CC1=CC(=NN1)NC2=C(C=C(C(=N2)N[C@@H](C)C3=CC=C(C=C3)F)C#N)F. Drug target is JAK2, JAK3. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning: AZ960 is a JAK1, 2, 3 inhibitor. JAK1, 2, 3 are downstream of various receptors and play a role in cytokine signaling. Mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1 can be found in various cancers. However, AZ960 has been shown to have good efficacy in FLT3-positive acute myeloid leukemia and other hematological malignancies. In vitro studies have shown that AZ960 can induce apoptosis in FLT3-positive leukemia cells. Additionally, AZ960 has been shown to have synergistic effects with other drugs, such as venetoclax, in FLT3-positive leukemia. In vitro studies have also shown that AZ960 can inhibit the growth of various cancer cell lines, including those with NOTCH1 mutations. Therefore, AZ960 is expected to be effective in the cell line with the given mutations."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SCH772984. The drug SMILES structure is O=C([C@H]1CN(CC(N2CCN(C3=CC=C(C4=NC=CC=N4)C=C3)CC2)=O)CC1)NC5=CC6=C(NN=C6C7=CC=NC=C7)C=C5. Drug target is ERK1, ERK2. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, ASXL1, U2AF1, which are associated with resistance to SCH772984."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PODOPHYLLOTOXIN. The drug SMILES structure is COC1=CC(=CC(=C1OC)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)O. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Podophorylotoxin is a potent inhibitor of MAP3K1, but the cell line has a mutation in MAP3K1. Therefore, the drug is unlikely to be effective in this case. Additionally, the cell line has mutations in FLT3, NOTCH1, and TP53, which are known to be associated with resistance to podophorylotoxin."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NVP-BEZ235. The drug SMILES structure is CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5. Drug target is PI3K (class 1), MTORC1, MTORC2. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant, FLT3 dependency. The cell line has mutations in ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1, and ASXL1 is a key epigenetic regulator of FLT3. MAP3K1 is a key regulator of the ERK signaling pathway. The cell line is expected to be resistant to NVP-BEZ235 due to the FLT3 dependency."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GSK690693. The drug SMILES structure is CCN1C2=C(C(=NC=C2OC[C@H]3CCCNC3)C#CC(C)(C)O)N=C1C4=NON=C4N. Drug target is AKT1, AKT2, AKT3. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. Resistance to GSK690693 has been reported in FLT3-positive acute myeloid leukemia and FLT3-positive acute lymphoblastic leukemia. In vitro studies have shown that GSK690693 is less effective against FLT3-positive leukemia cells with certain mutations, such as FLT3 internal tandem duplication (ITD) and FLT3 point mutations. In addition, MAP3K1 is a known negative regulator of the PI3K/MTORC1 pathway, and GSK690693 is an AKT inhibitor. Therefore, the cell line's resistance to GSK690693 may be due to the presence of FLT3 ITD, FLT3 point mutations, and MAP3K1."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SORAFENIB. The drug SMILES structure is CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F. Drug target is PDGFR, KIT, VEGFR, RAF. Drug target pathway is RTK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Sorafenib is a multikinase inhibitor, and the cell line has mutations in MAP3K1, NOTCH1, and TP53, which are associated with resistance to sorafenib."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GSK591. The drug SMILES structure is C1CC(C1)NC2=NC=CC(=C2)C(=O)NC[C@@H](CN3CCC4=CC=CC=C4C3)O. Drug target is PMRT5. Drug target pathway is Chromatin histone methylation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, the drug GSK591 is an inhibitor of FLT3, MAP3K1, and NOTCH1, making it less suitable for cell lines with these mutations."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is DAPORINAD. The drug SMILES structure is C1CN(CCC1CCCCNC(=O)C=CC2=CN=CC=C2)C(=O)C3=CC=CC=C3. Drug target is NAMPT. Drug target pathway is Metabolism.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. DAPORINID is an investigational agent that has been shown to sensitize FLT3-positive AML to chemotherapy. However, the mutations in this cell line include FLT3, MAP3K1, NOTCH1, P53, U2AF1, making it resistant to DAPORINID."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PFI-1. The drug SMILES structure is CN1CC2=C(C=CC(=C2)NS(=O)(=O)C3=CC=CC=C3OC)NC1=O. Drug target is BRD4. Drug target pathway is Chromatin other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
PFI-1 is a selective BRD4 inhibitor. BRD4 is a chromatin-associated protein that interacts with acetylated lysine 142 of H3 histones. PFI-1 has been shown to inhibit the growth of FLT3-ITD positive leukemia cells. In addition, PFI-1 has been shown to inhibit the growth of various cancer cell lines, including those with MAP3K1, NOTCH1, TP53, and U2AF1 mutations. Therefore, PFI-1 is expected to be effective against the cell line with the given mutations."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TPCA-1. The drug SMILES structure is C1=CC(=CC=C1C2=CC(=C(S2)NC(=O)N)C(=O)N)F. Drug target is IKK2. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. TPCA-1 is an inhibitor of IKKb, which is the catalytic subunit of the IKK complex. IKKb plays a role in the NF-κB signaling pathway. TPCA-1 has been shown to inhibit the proliferation of FLT3-ITD and MAP3K13C mutant cells. However, the cell line in question has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which may affect its response to TPCA-1. In particular, the MAP3K1 mutation may make the cell line resistant to TPCA-1, as MAP3K1 is a key component of the ERK signaling pathway, which is downstream of the IKK pathway. Additionally, the TP53 mutation may contribute to resistance by increasing the ability of the cell to evade apoptosis."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CP466722. The drug SMILES structure is COC1=C(C=C2C(=C1)C(=NC=N2)N3C(=NC(=N3)C4=CC=CC=N4)N)OC. Drug target is ATM. Drug target pathway is Genome integrity.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
CP466722 is a MAP3K1 inhibitor. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. MAP3K1 is a tumor suppressor gene, and mutations in this gene can lead to tumor development. However, the cell line does not have many driver mutations, and the only oncogenic mutation is in U2AF1, which is not a driver mutation for FLT3 or MAPK signaling. Therefore, the cell line is expected to be sensitive to CP466722."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NILOTINIB. The drug SMILES structure is CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)N3C=C(N=C3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5. Drug target is ABL. Drug target pathway is ABL signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.

Reasoning:
NILOTINIB is a tyrosine kinase inhibitor of the ABL gene, specifically for the BCR-ABL and EGF receptors. It is also an effective inhibitor of the c-Kit and PDGFR alpha and beta receptors. In the case of the cell line with mutations in FLT3, MAP3K1, NOTCH1, TP53, and U2AF1, NILOTINIB is known to be effective in FLT3-positive acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML). In addition, MAP3K1 mutations are less common in CML, and NOTCH1 mutations are less common in CML and acute myeloid leukemia (AML). TP53 mutations are associated with resistance to various drugs, but NILOTINIB is not one of them. U2AF1 mutations are linked to drug resistance, but NILOTINIB is still effective in some cases. Overall, NILOTINIB is a first-"
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is (5Z)-7-OXOZEAENOL. The drug SMILES structure is CC1CC=CC(=O)C(C(CC=CC2=C(C(=CC(=C2)OC)O)C(=O)O1)O)O. Drug target is TAK1. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. The drug (5Z)-7-Oxozeaenol is an MTD1 agonist and MTD1 is a kinase that promotes cell proliferation. In cell lines with FLT3 mutations, this drug may exacerbate the FLT3 signaling and contribute to resistance. Additionally, the cell line has mutations in MAP3K1, NOTCH1, TP53, and U2AF1, which are associated with resistance to various drugs."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SUNITINIB. The drug SMILES structure is CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C. Drug target is PDGFR, KIT, VEGFR, FLT3, RET, CSF1R. Drug target pathway is RTK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Sunitinib is a multi-kinase inhibitor. Resistance to sunitinib can be due to various mechanisms such as mutations in the PTK2, MAP2K1, AKT2, KDR, EP3D1, MAP3K13, RAD54L, TP53, BRCA2, EGFR, EPHB1, EPHB4, ERBB4, KIT, MLL2, MED12, NTRK3, RNF43, SMARCA4, TET2, TP53, WHSC1L1. In the case of the given mutations, the cell line has mutations in ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1. ASXL1 mutations can lead to epigenetic alterations, FLT3 mutations can lead to FLT3 activation, MAP3K1 mutations can lead to ERK1 and ERK2 activation, NOTCH1 mutations can lead to NOTCH1 activation. TP53 mutations can lead to various cellular processes"
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FH-535. The drug SMILES structure is CC1=C(C=CC(=C1)[N+](=O)[O-])NS(=O)(=O)C2=C(C=CC(=C2)Cl)Cl. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
The cell line is T-cell acute lymphoblastic leukemia (T-ALL) with FLT3, MAP3K1, NOTCH1, TP53, U2AF1 mutations. FH-535 is an unknown drug target. However, FH-535 is a PI3K activator. T-ALL with FLT3, MAP3K1, NOTCH1, TP53, U2AF1 mutations are resistant to FH-535."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FLUDARABINE. The drug SMILES structure is C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N. Drug target is Antimetabolite. Drug target pathway is DNA replication.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning: Fludarabine is an antimetabolite that is commonly used in the treatment of chronic lymphocytic leukemia and other types of leukemia. It is a nucleoside analog that inhibits DNA and RNA synthesis. The mutations in the cell line include ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1. ASXL1 is a gene that is commonly mutated in myeloid neoplasms. It is a member of the ALK and FLT3 signaling pathways and is involved in epigenetic regulation. FLT3 is a receptor tyrosine kinase that is commonly mutated in acute leukemia. MAP3K1 is a gene that encodes ERK3, a member of the ERK signaling pathway. NOTCH1 is a gene that is commonly mutated in various types of cancer. TP53 is a gene that encodes the tumor suppressor protein p53. U2AF1 is a gene that encodes a protein that plays a role in splicing RNA. Fludarabine is considered to be sensitive to most types of leuk"
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BIBR-1532. The drug SMILES structure is CC(=CC(=O)NC1=CC=CC=C1C(=O)O)C2=CC3=CC=CC=C3C=C2. Drug target is TERT. Drug target pathway is Genome integrity.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in MAP3K1, NOTCH1, TP53, and U2AF1, and BIBR-1532 is reported to be resistant in cells with MAP3K1 mutations."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is OBATOCLAX. The drug SMILES structure is CC1=CC(=C(N1)C=C2C(=CC(=C3C=C4C=CC=CC4=N3)N2)OC)C. Drug target is BCL2, BCL-XL, BCL-W, MCL1. Drug target pathway is Apoptosis regulation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.Obatoclax is a BCL-2, BCL-XL, and MCL-1 antagonist. The cell line has mutations in FLT3, MAP3K1, NOTCH1, and TP53, which are known to be resistant to BCL-2 antagonists."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TOPOTECAN. The drug SMILES structure is CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC(=C(C5=C4)CN(C)C)O)O. Drug target is TOP1. Drug target pathway is DNA replication.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. Topotecan is an effective agent for FLT3-WT acute myeloid leukemia (AML), but the cell line in question has FLT3 and MAP3K1 mutations, making it resistant to topotecan."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PONATINIB. The drug SMILES structure is CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5. Drug target is ABL, PDGFRA, VEGFR2, FGFR1, SRC, TIE2, FLT3. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning: Ponatinib is a multi-kinase inhibitor that includes PDGFRA, FLT3, KIT, EGFR, VEGFR1, VEGFR3, FGFR1, AXL, EGFR, ERBB2, EGFR, BCR, AKT, EGFR, RAS, EGFR, EGFR, EGFR, EGFR, EGFR, EGFR, EGFR, EGFR, EGFR, FGFR1, FGFR2, FGFR3, FGFR3, FGFR3, FGFR3, FGFR3, FGFR3, FGFR3, FGFR3, FGFR3, FGFR3, FGFR3, FGFR3, FGFR3, FGFR3, FGFR3, FGFR3, FGFR3, FGFR3, FGFR3, FGFR3, FG"
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TENOVIN-6. The drug SMILES structure is CC(C)(C)C1=CC=C(C=C1)C(=O)NC(=S)NC2=CC=C(C=C2)NC(=O)CCCCN(C)C. Drug target is SIRT. Drug target pathway is Chromatin histone acetylation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, the drug TENOVIN-6 is an investigational new drug with limited data on sensitivity in various cancers."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is MIDOSTAURIN. The drug SMILES structure is C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC. Drug target is PKC, PPK, FLT1, c-FGR, others. Drug target pathway is Other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with resistance to midostaurin."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SN-38. The drug SMILES structure is CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)O. Drug target is TOP1. Drug target pathway is DNA replication.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. SN-38 is a topoisomerase I inhibitor.Resistant mutations in the cell line include FLT3, MAP3K1, NOTCH1, TP53, U2AF1. FLT3 and MAP3K1 are resistance mechanisms for SN-38. FLT3 mutations lead to increased signaling through the FLT3 receptor, making the cells more resistant to SN-38. MAP3K1 mutations can lead to increased ERK signaling, which can make cells more resistant to SN-38. The cell line also has mutations in U2AF1, which can lead to resistance to various drugs, including SN-38."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AR-42. The drug SMILES structure is CC(C)[C@@H](C1=CC=CC=C1)C(=O)NC2=CC=C(C=C2)C(=O)NO. Drug target is HDAC1. Drug target pathway is Chromatin histone acetylation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. The drug AR-42 is an HDAC1 inhibitor. HDAC1 inhibition can induce apoptosis and cell cycle arrest. However, the cell line has multiple mutations, including FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which can affect its response to the drug. For example, FLT3 mutations can make the cell line resistant to FLT3 inhibitors. MAP3K1 mutations can impair the cell cycle arrest and apoptosis induced by HDAC1 inhibitors. NOTCH1 mutations can contribute to the resistance to HDAC1 inhibitors by activating survival pathways. TP53 mutations can impair the ability of the cell to undergo apoptosis in response to DNA damage induced by HDAC1 inhibitors. U2AF1 mutations can impair the splicing of key genes, including those involved in the DNA damage response. Overall, the presence of multiple mutations in the cell line makes it resistant to AR-42."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BMS-536924. The drug SMILES structure is CC1=CC(=CC2=C1NC(=C3C(=CC=NC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N2)N5CCOCC5. Drug target is IGF1R, IR. Drug target pathway is IGF1R signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with resistance to BMS-536924."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZD3759. The drug SMILES structure is C[C@@H]1CN(CCN1C(=O)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC)C. Drug target is EGFR. Drug target pathway is EGFR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line is mutated in the genes MAP3K1, NOTCH1, TP53. AZD3759 is an EGFR inhibitor. These mutations are not commonly associated with EGFR mutations, and EGFR mutations are not commonly associated with these mutations. Therefore, it is unlikely that the cell line is sensitive to AZD3759."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ENTINOSTAT. The drug SMILES structure is C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3. Drug target is HDAC1, HDAC3. Drug target pathway is Chromatin histone acetylation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
Entinostat is a histone deacetylase (HDAC) inhibitor. HDAC inhibitors can modify chromatin structure, making it more accessible for transcription factors to bind and activate gene expression. This can lead to cell cycle arrest and apoptosis in cancer cells. The mutations in the cell line do not have a significant impact on the drug sensitivity of entinostat."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AT7867. The drug SMILES structure is C1CNCCC1(C2=CC=C(C=C2)C3=CNN=C3)C4=CC=C(C=C4)Cl. Drug target is AKT. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
The cell line is mutated in the genes ASXL1, FLT3, MAP3K1, NOTCH1, P53, U2AF1, making it resistant to AT7867. This drug is an AKT inhibitor, and the cell line has mutations in multiple pathways, including FLT3, MAP3K1, NOTCH1, P53, and U2AF1, making it resistant to this drug."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TASELISIB. The drug SMILES structure is CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C. Drug target is PI3K (beta sparing). Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning: TASELISIB is a PI3K delta inhibitor. PI3K delta mutations are common in FLT3-ITD negative ACPC with ASXL1 mutations. However, in this case, the cell line has a FLT3 mutation, making it less likely to have a PI3K delta mutation. Additionally, ASXL1 mutations are often associated with PI3K and TP53 mutations, but this cell line has both ASXL1 and TP53 mutations. The cell line also has a MAP3K1 mutation, which is not commonly associated with PI3K delta mutations. Therefore, it is likely that this cell line does not have a PI3K delta mutation and may be sensitive to TASELISIB."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is WEHI-539. The drug SMILES structure is C1CC2=C(C=C(C=C2)C3=NC(=C(S3)CCCOC4=CC=C(C=C4)CN)C(=O)O)C(=NNC5=NC6=CC=CC=C6S5)C1.Cl. Drug target is BCL-XL. Drug target pathway is Apoptosis regulation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, the drug target BCL-XL is a member of the BCL2 family and is known to be overexpressed in some cancers, making cells resistant to apoptosis-inducing drugs."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LJI308. The drug SMILES structure is C1COCCN1C2=CC=C(C=C2)C3=C(C=NC=C3)C4=CC(=C(C(=C4)F)O)F. Drug target is RSK2, RSK1, RSK3. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, LJI308 is an ATR inhibitor, and ATR inhibition can induce resistance to various drugs. In the absence of other sensitizing mutations, LJI308 is not expected to be effective against cells with these mutations."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is APABETALONE. The drug SMILES structure is CC1=CC(=CC(=C1OCCO)C)C2=NC3=C(C(=CC(=C3)OC)OC)C(=O)N2. Drug target is BRD4. Drug target pathway is Chromatin other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. APABETALONE is a GNAS agonist and MAP3K13 inhibitor. Resistance to APABETALONE can be due to mutations in GNAS, MAP3K13, or other genes involved in the WNT signaling pathway. In the case of the cell line with mutations in ASXL1, FLT3, MAP3K1, NOTCH1, and TP53, it is likely that other pathways are also involved in the resistance to APABETALONE."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BLEOMYCIN. The drug SMILES structure is CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H](C(C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O. Drug target is dsDNA break induction. Drug target pathway is DNA replication.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
Reasoning: The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. Fluorouracil, a component of Bleomycin, is an inhibitor of multiple enzymes in the RNA synthesis and DNA synthesis. Mutations in MAP3K1, NOTCH1, TP53 can affect the sensitivity"
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BAY-61-3606. The drug SMILES structure is COC1=C(C=C(C=C1)C2=CC3=NC=CN3C(=N2)NC4=C(C=CC=N4)C(=O)N)OC. Drug target is SYK. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, the drug target SYK is not mutated in the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GSK269962. The drug SMILES structure is CCN1C2=CC(=NC=C2N=C1C3=NON=C3N)OC4=CC=CC(=C4)NC(=O)C5=CC=C(C=C5)OCCN6CCOCC6. Drug target is ROCK1, ROCK2. Drug target pathway is Cytoskeleton.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with resistance to GSK269962. Additionally, GSK269962 is an inhibitor of ROCK1, ROCK2, and other kinases. The cell line's mutations in MAP3K1 and NOTCH1 may affect the drug's effectiveness. Furthermore, the cell line has mutations in U2AF1, which may affect the drug's ability to bind to its target."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is DMOG. The drug SMILES structure is COC(=O)CNC(=O)C(=O)OC. Drug target is HIF-PH. Drug target pathway is Metabolism.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Sensitive.
DMOG is a CGP11077 derivative that is a small-molecule inhibitor of the alpha-keto-glutarate dehydrogenase complex. It is a hypoxia-mimetic agent that can induce HIF-alpha stabilization and activation of hypoxia-responsive genes. DMOG can also inhibit the JAK2 kinase. In the context of the mutations in the cell line, DMOG is expected to be sensitive as the cell line has mutations in the MAP3K1 gene, which is the upstream kinase in the ERK signaling pathway, and the KRAS pathway, which is a downstream effector of the ERK signaling pathway. Mutations in these pathways can result in increased cell proliferation and survival, making them potential targets for anticancer drugs. However, DMOG is not specifically targeting these pathways, but rather mimicking the hypoxic conditions, which can induce cell death in various ways. Therefore, the sensitivity of the cell line to DMOG may not be solely dependent on the mutations in the KRAS pathway, but also on other factors such as the cellular response to hypoxia."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is C-75. The drug SMILES structure is CCCCCCCCC1C(C(=C)C(=O)O1)C(=O)O. Drug target is FAS. Drug target pathway is Apoptosis regulation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
The mutations in the cell line include FLT3, MAP3K1, NOTCH1, TP53, U2AF1. C-75 is a pan-cancer agent that can affect multiple pathways. However, it is particularly known for its ability to induce apoptosis. The mutations in the cell line include FLT3, MAP3K1, NOTCH1, TP53, U2AF1. MAP3K1 and TP53 are tumor suppressor genes. NOTCH1 is a proto-oncogene. U2AF1 is a splicing factor. These mutations can contribute to drug resistance by various mechanisms, including impaired apoptosis, impaired cell cycle control, and impaired DNA damage response. C-75 may be less effective in cells with these mutations due to these mechanisms."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is HG-5-113-01. The drug SMILES structure is CC(C)S(=O)(=O)C1=CC=CC=C1NC2=CC(=NC3=C2C=CN3)NC4=NC=C(C=C4)C(=O)NC. Drug target is AURKA. Drug target pathway is Mitosis.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. The cell line has mutations in MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, the drug target is AURKA, which is a mitotic kinase, and the drug SMILES structure includes a CC(C)S moiety, which is a common feature of AURKA inhibitors. The cell line mutations include FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Therefore, the drug is likely to be resistant to the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AS605240. The drug SMILES structure is C1=CC2=NC=CN=C2C=C1C=C3C(=O)NC(=O)S3. Drug target is PI3Kgamma. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Sensitive.
Reasoning:
ASXL1 mutation can lead to resistance to various drugs. However, in this case, the drug AS605240 is an AKT1, AKT2, and ROCK2 inhibitor. AKT1 and AKT2 mutations are not common in the cell line. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, but these mutations do not make the cell line resistant to AS605240. The drug is known to have good efficacy against various cancer cell lines, including the one with the given mutations. Therefore, the drug sensitivity is Sensitive."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is APITOLISIB. The drug SMILES structure is CC1=C(SC2=C1N=C(N=C2N3CCOCC3)C4=CN=C(N=C4)N)CN5CCN(CC5)C(=O)[C@H](C)O. Drug target is mTOR, PI3K. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. APITOLISIB is an mTOR and PI3K inhibitor. However, the cell line has mutations in MAP3K1, NOTCH1, TP53, U2AF1, which can make it resistant to PI3K inhibitors."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is YM-155. The drug SMILES structure is CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]. Drug target is BIRC5. Drug target pathway is Apoptosis regulation.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. YM-155 is a BIRC5 (BCL2-binding protein 1) inhibitor. However, the cell line's resistance is not solely due to the drug target."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is OTX015. The drug SMILES structure is CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)NC4=CC=C(C=C4)O)C5=CC=C(C=C5)Cl)C. Drug target is BRD2, BRD3, BRD4. Drug target pathway is Chromatin other.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning: The drug OTX015 is an HDAC inhibitor. The cell line has mutations in ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. In particular, FLT3, MAP3K1, NOTCH1, TP53 mutations are often associated with drug resistance. ASXL1 mutations can also contribute to drug resistance by impairing the epigenetic regulation of genes. U2AF1 mutations can also lead to drug resistance by impairing the splicing of genes. Therefore, the cell line is predicted to be resistant to OTX015."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is JNK INHIBITOR VIII. The drug SMILES structure is CCOC1=C(C(=CC(=N1)NC(=O)CC2=C(C=CC(=C2)OC)OC)N)C#N. Drug target is JNK. Drug target pathway is JNK and p38 signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are associated with drug resistance. Additionally, JNK INHIBITOR VIII is a specific JNK inhibitor, and the cell line does not have any known JNK mutations. Therefore, it is unlikely that the drug would be sensitive for this cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is YM-201636. The drug SMILES structure is C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)NC(=O)C6=CN=C(C=C6)N. Drug target is PIKFYVE. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.
Reasoning:
YM-201636 is a PI3K inhibitor. The cell line has mutations in MAP3K1, NOTCH1, TP53. MAP3K1 mutations can make the cell line resistant to PI3K inhibitors. However, the cell line does not have any known resistance mutations in the PI3K pathway other than MAP3K1. Additionally, the cell line has mutations in ASXL1, U2AF1, which can contribute to epigenetic changes and splicing, respectively, but are not directly related to PI3K pathway. Therefore, the drug is expected to be sensitive to the cell line."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is IDELALISIB. The drug SMILES structure is CC[C@@H](C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5. Drug target is PI3Kdelta. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Sensitive.IDEALISIB is a PI3Kdelta inhibitor.ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1 mutations do not affect PI3Kdelta signaling pathway.Therefore, the drug sensitivity is Sensitive."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is RIBOCICLIB. The drug SMILES structure is CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5. Drug target is CDK4, CDK6. Drug target pathway is Cell cycle.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, making it resistant to RIBOCICLIB. The drug targets CDK4, CDK6, and CIML-1 has reported cases of resistance in cell lines with mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is APR-246. The drug SMILES structure is COCC1(C(=O)C2CCN1CC2)CO. Drug target is TP53 activation. Drug target pathway is p53 pathway.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant.
Reasoning: APR-246 is a p53 reactivator. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. FLT3 and MAP3K1 mutations make the cell line resistant to APR-246."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TRAMETINIB. The drug SMILES structure is CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC(=CC=C4)NC(=O)C)C5CC5. Drug target is MEK1, MEK2. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant. The cell line has mutations in MAP3K1 and NOTCH1, which are associated with resistance to TRAMETINIB."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ALVOCIDIB. The drug SMILES structure is CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Resistant.
Reasoning: The drug ALVOCIDIB is a mitotic spindle poison. The cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1. These mutations can contribute to drug resistance. For example, FLT3 mutations can lead to resistance to FLT3 inhibitors. MAP3K1 mutations can lead to resistance to MEK inhibitors. NOTCH1 mutations can lead to resistance to BET inhibitors. TP53 mutations can lead to resistance to various drugs by impairing apoptosis and DNA repair. U2AF1 mutations can lead to resistance to drugs that require RNA splicing, such as BCL2L1. Therefore, the cell line is likely to be resistant to ALVOCIDIB."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is MIRIN. The drug SMILES structure is C1=CC(=CC=C1C=C2C(=O)N=C(S2)N)O. Drug target is MRE11. Drug target pathway is Genome integrity.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Resistant,"Sensitive.
Reasoning:
MIRIN is a Farnesyltransferase inhibitor. Farnesyltransferase is required for the post-translational modification of RAS and other RAS-related proteins. Inhibition of farnesyltransferase disrupts the signaling of these proteins, leading to cell death. The mutations in the cell line do not confer resistance to MIRIN. In fact, the cell line has mutations in FLT3, MAP3K1, NOTCH1, TP53, U2AF1, which are often associated with resistance to various drugs. However, these mutations are not known to confer resistance to MIRIN."
ACH-000006,"<s>[INST] <<SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line: [Sensitive/Resistant]<</SYS>>Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PI-103. The drug SMILES structure is C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)O. Drug target is PI3Kalpha, DAPK3, CLK4, PIM3, HIPK2. Drug target pathway is Other, kinases.
The mutations of the cell line are ['ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1'].
Drug Sensitivity: ?[/INST]",Sensitive,"Resistant. PI3K inhibitors are generally resistant in cells with MAP3K1 mutations. PI-103 is a PI3K inhibitor, and MAP3K1 mutations can lead to resistance to this class of drugs."
